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CHAPTER I
THE ROLE OF p53 AND HDM2 IN LYMHPHOMA
Introduction to Lymphoma
Lymphoma, a complex, heterogeneous set of lymphocyte malignancies, is the
most common hematological malignancy in the United States.

Lymphomas are

classified into one of two major groups: Hodgkin lymphoma (HL) and non-Hodgkin’s
lymphoma (NHL), the former being less common than the latter (Table 1.1). Both HL
and NHL display variable behavioral characteristics and respond differently to
treatment. It is estimated that over 660,000 people in the United States are currently
living with, or are in remission from, lymphoma.
Table 1.1 Projected New Cases and Estimated Deaths from Lymphoma in the U.S.
2012.
New Cases
Deaths
Type
Total
Male
Female
Total
Male
Female
Hodgkin
9,060
4,960
4,100
1,190
670
520
Lymphoma
Non-Hodgkin’s
70,130
38,160
31,970
18,940
10,320
8,620
Lymphoma
Total
79,190
43,120
36,070
20,130
10,990
9,140
Source: Cancer Facts and Figures, 2012. American Cancer Society: 2012.

Non-Hodgkin lymphoma
Over 70,000 new cases of NHL will afflict individuals in the U.S. in 2012, 5% of
all cancer cases and 3% of all cancer related deaths (1). The incidence of NHL in the
U.S. has risen more than 82.5% from 1975-2008, an average of 3% annually (2).
Cancer rates increase with age of the population but age is not the only factor
contributing to these increases (Figure 1.1) (2). Despite the alarmingly high incidence,
mortality rates have decreased dramatically since the turn of the century (Figure 1.1)
(2). This could be attributed to detection of differences in the biology of the tumor as a
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result of scientific advancements, and more personalized therapy.

Figure 1.1 Age-adjusted SEER (Surveillance Epidemiology and End Results) incidence
and mortality rates of NHL by sex (2).
Since NHL comprises many disease subtypes each with different biological
characteristics and prognosis, classifying lymphomas is essential to diagnosis and
subsequent treatment strategy. NHL was initially classified based on histopathologic
appearance and placed into 1 of 3 subtypes in 1966 (3, 4).

More sophisticated

diagnostic tests have been implemented as research has progressed resulting in
frequent modification of classification systems. Currently, the World Heath Organization
(WHO) has classified more than 60 subtypes based on a combination of morphology,
immunophenotype, genetic and clinical features (5). Approximately 85% derive from B
lymphoctyes where the origin of disease can be located at a certain stage of B cell
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differentiation within precursor or peripheral cells. The rest comprise T cell and natural
killer (NK) cell lymphomas. This study focused primarily on B cell NHL.
NHL cells contain antigenic markers that are identified by immunohistochemistry
(IHC) and flow cytometry. Genetic abnormalities are often associated with lymphomas,
particularly chromosomal translocations, insertions, or deletions detected by karyotyping
or fluorescent in situ hybridization (FISH). These abnormalities may play a role in the
pathogenesis of specific subtypes of NHL and some are currently important prognostic
factors.
The stage, or extent of the spread of disease, is established after diagnosis and
determines the prognosis and treatment. In 1966, lymphoma was the first disease for
which a tumor staging system was recommended, as exemplified by the Rye staging
(6). The Cotswolds modified Ann Arbor staging system is in use at the current time (7,
8) Table 1.2 (9, 10).
Table 1.2. Cotswolds modified Ann Arbor staging system for NHL. (7)
Stage
Definition
I
II
III

IV

The tumor is located to a single region, usually 1 lymph node and the
surrounding area.
The tumor is located in multiple regions on the same side of the
diaphragm.
The disease has spread to the lymph nodes on both sides of the
diaphragm (III1) or the disease has spread into an area or organ next to
the lymph node (III2).
Diffuse involvement of extranodal sites beyond those designated in E,
including bone marrow, liver, brain, or pleura.

Suffixes:
E, involvement of one extranodal site, contiguous or proximal to identified nodal site of disease.
X, presence of bulky disease >10 cm.
Stage followed by A or B where:
A- no disease symptoms
B- presence of disease symptoms; >10% body mass reduction in 6 month period, fevers of ≥ 38ºC
for 3 consecutive days or more, recurrent drenching night sweats.

The behavior of NHL may be characterized as indolent, aggressive or very
aggressive. Aggressive lymphomas are fast growing and high grade, but are potentially
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curable. The cure rate depends on a number of prognostic factors as outlined in the
International Prognostic Index (IPI) and can vary from 26% to 73% (11). Diffuse large
B-cell lymphoma (DLBCL) accounts for 31% of all NHL (12) and serves as a paradigm
for the treatment of aggressive lymphomas whereas very aggressive lymphomas are
exemplified by Burkitt’s lymphoma (BL). These are some of the most curable forms and
are expected to be more responsive since current chemotherapies target actively
dividing cells (13). Indolent lymphomas are slow growing and relatively low grade, and
are currently incurable with existing treatment regimens. Follicular lymphoma (FL)
constitutes 30-35% of all NHL and is considered to be the prototypical indolent type
(14). Because of their slow growing nature, it is difficult to predict treatment outcome for
indolent NHL.

The Follicular Lymphoma International Prognostic Index (FLIPI) has

established 5 factors that assist in outcome prediction and is a modification of the IPI for
less aggressive NHL (15).

These prognostic factors are age, stage III or IV, low

hemoglobin levels (<12 gm/dL), greater than 4 lymph node sites affected, and elevated
LDH levels. Other indolent subtypes include chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL), marginal zone lymphoma (MZL), and Waldenstrom’s
macroglobulinemia (WM) which is a lymphoplasmacytic lymphoma.
Hodgkin lymphoma (HL)
Over 9,000 new cases of HL are predicted to occur in the U.S. in 2012 resulting
in an estimated 1,000 deaths (1) (Table 1).

Overall incidence rates of HL have

decreased, but there has been a slight increase in young adults (16). As with NHL,
mortality rates in the U.S. have decreased from 1975-2009 (Figure 1.2).
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Figure 1.2. Age-adjusted SEER incidence and mortality rates in HL in both males and
females (2).
HL was initially described by Thomas Hodgkin in 1832 and the disease was later
named after him (17).

Giant, multinucleated Reed-Sternberg (RS) cells are a

characteristic feature of HL. RS cells typically contain two nuclei but can be
multinucleated or mononuclear and are thought to be of B cell origin. Infiltration of
reactive cell types with the RS cells defines specific HL subtypes. HL is broadly divided
into two categories: 1.) nodular lymphocyte-predominant HL (approximately 5% of all HL
cases) (18) and 2.) classical HL (cHL) (the remaining 95%) consisting of nodular
sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte depleted types.
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Treatment of lymphomas
Treatment for lymphomas is generally based on stage of disease and histologic
subtype and varies from NL to NHL. Therapeutic options for B-cell lymphomas consist
of conventional cytotoxic chemotherapeutics, radiation therapy, immunotherapy or stem
cell transplantation (SCT).

Since the 1970’s, a combination of cyclophosphamide,

doxorubicin, vincristine and prednisone (CHOP) has been the standard form of cytotoxic
therapy for NHL.

Indolent lymphomas frequently undergo initial ‘watch and wait’

approach since they are incurable. Although very aggressive lymphomas are curable
with intensive chemotherapy, there is no standard treatment. Alternative chemotherapy
regimens incorporating higher doses of additional cytotoxic agents like methotrexate
and cytosine arabinoside (Ara-C) were shown to improve therapeutic efficacy. The cure
rate with chemotherapy alone has reached a plateau of approximately 40% for
aggressive NHL subtypes (19).

Radiation can be used in conjunction with

chemotherapy or at relapse, with or without SCT. Despite the initial activity of these
regimens, overall efficacy is limited due to high toxicity or disease resistance.
A combination of doxorubicin, bleomycin, vinblastine, and decarbazine (ABVD)
has been the standard chemotherapy regimen for HL with or without radiotherapy,
depending on stage and histological grade. In use since the mid-1970’s, this regimen
has been shown to provide patients with the highest efficacy and the lowest toxicity (2022). Although the majority of HL patients are cured with current treatment modalities,
relapse can, and does, occur with a worse outcome (23, 24). Long-term toxicity such as
infertility,

development

of

secondary

tumors,

premature

menopause,

and

cardiopulmonary complications are also major concerns and a challenge to overcome.
Extensive recent research efforts have paved the way to a better understanding
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of the molecular pathobiology of lymphomas. This has provided new clues on how to
exploit the underlying pathogenesis for therapeutic intervention. One such approach is
the development of a monoclonal antibody, rituximab, specifically targeting the CD20
antigen expressed on B-cell neoplasms. When added to CHOP (i.e. R-CHOP), the
event free survival (EFS) in patients with aggressive NHL was increased approximately
16% (25), and 18% in patients with indolent NHL (26). However, the overall survival of
indolent lymphoma has not significantly improved even with the success of rituximab as
a targeted therapy (26, 27), suggesting that the underlying biology of the disease largely
dictates outcome.
As in the majority of human cancers, levels and activation of tumor suppressors
and proto-oncogenes are deregulated in lymphomas (28). However, in contrast to most
solid tumors, the course of proto-oncogene activation, at least in NHL, is via
chromosomal translocations. Regardless, presence of a translocation alone is not
sufficient to drive lymphomagenesis as they are infrequently found in HL (29). Indeed, a
number of different genetic lesions and alterations to signal transduction pathways
appear to be important in defining events implicated in the pathogenesis of lymphomas
(28). Many of these alterations are becoming more and more useful as prognostic
predictors in both NHL and HL, particularly the p53 pathway, which is part of the
ubiquitin proteasome system (UPS), and an important focus of this study.
Most importantly, identification of molecular defects has led to the development
of novel targeting agents. This is reflected by the numerous preclinical and clinical trials
investigating targeted therapeutics to several different molecular targets. The challenge
is to identify highly selective agents that will complement conventional chemotherapy to
reduce toxicity and improve survival rates when managing both HL and NHL.
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Of particular interest and primary focus of this study is the p53-HDM2 proteinprotein interaction, a pathway within the ubiquitin proteasome system (UPS), and the
preclinical assessment of novel anti-cancer agents to target p53-HDM2 disruption in
lymphoma cells.
Role of the ubiquitin-proteasome system
The ubiquitin-proteasome system (UPS) is perhaps the most important pathway
for monitoring eukaryotic cell proteolytic activity.

An estimated 80-90% of protein

degradation is thought to be regulated by the UPS. Both short- and long-lived proteins
are continually destroyed at variable half-lives and restored by de novo synthesis (30,
31).

The UPS causes rapid substrate proteolysis which inactivates and eliminates

damaged, oxidized, or misfolded proteins before they aggregate (32), serving an
essential role in the maintenance of physiologic function of intracellular proteins.
Because the UPS serves to sustain cellular homeostasis and critical mechanisms
exist to regulate its function precisely and with high specificity, it should come as no
surprise that alterations to components of the UPS have been associated to a variety of
human diseases, including cancer. Many deregulated signaling pathways in cancer
cross-talk with the UPS by undergoing ubiquitination and proteasomal degradation.
Some of the proteins targeted for degradation include transcription factors, cell cycle
regulators, and signal transducers that are involved in numerous signaling pathways
and biological processes such as cell division, apoptosis, DNA repair, cell cycle arrest,
transcriptional regulation, differentiation and endocytosis (33, 34). In fact, p53 is heavily
regulated by various components of the UPS, particularly by its predominant negative
regulator, HDM2.
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p53: Guardian of the genome
In 1979, the T-antigen of simian virus 40 (SV40) was found to be associated with
a 53 kilodalton (kDa) protein (35). Protein 53 (p53, protein product of the TP53 gene),
was initially identified as an oncogene (36). However, extensive studies determined that
the T-antigen of SV40, a viral oncogene, was blocking p53 activity and not vice versa
since wt-p53 was unable to transform cells in culture. It later became clear that the
function of p53 was tumor suppressive rather than oncogenic (37-39), a paradigm shift
that occurred more than a decade after its discovery. Today, p53 is cited in over 62,000
literature publications and is viewed as the ‘guardian of the genome’ due to its role in
conservation of genomic stability and its involvement in development, aging, and
numerous diseases, particularly cancer. Furthermore, it is found in all cells, although
p53 expression and activity is both cell type and context specific.
More genetic errors arise with the loss of p53 function, leading to a higher
susceptibility to cancer. This was demonstrated in genetically engineered p53 null mice
(40). These mice developed spontaneous tumors at an early age and had a significantly
shorter life-span compared to heterozygous or wild-type p53 mice (40). Interestingly,
45-70% of these spontaneous tumors were lymphomas in p53 null mice from two
different strains. This highlighted the possibility that there may be underlying
predisposing cell- or tissue-specific factors in lymphoma and other cancers. Therefore,
the integrity of functional p53 activity is vital to the development and protection of
normal cells from cancer development.
Detection of p53 mutations and their alteration of tumor suppressor function were
initially discovered in most colon cancers in 1989 (38). Today, the importance of p53’s
function is underscored by its frequent mutation rate found in at least 50% of all cancers
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(41, 42). Interestingly, however, p53 mutations are far less prevalent in hematological
malignancies compared to solid tumors suggesting that p53 loss-of-function is important
to the course of cancer progression.
Structure and function
The human TP53 gene is located on the short arm of chromosome band
17p13.1, encoding a pleiotropic transcription factor (43). The predominant p53 mRNA
transcript consists of 11 exons, although the coding sequence lacks the 1st exon. The
resulting p53 protein product is composed of 393 amino acids (a.a) in length, divided
into five evolutionarily conserved domains that reflect a specific function (Figure 1.3).

Figure 1.3 Secondary structure of p53 tumor suppressor protein. Human p53 protein is
composed of five domains, each corresponding to specific functions.
These domains and their residues include: the transactivational domain (1-42
a.a), a proline-rich domain (63-97 a.a), a DNA-binding domain (DBD) (98-292 a.a), a
tetramerization domain (324-355 a.a), and a C-terminal regulatory domain (363-393 a.a)
(44). Additionally, p53 contains a nuclear localization signal sequence (NLS) and three
nuclear export signal sequences (NES) located within the tetramerization domain (44).
The transactivation domain is located at the N-terminus which interacts with cotranscription factors that aid in modulating gene expression. The proline-rich domain is
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also located at the N-terminus. Its function, which once was poorly characterized, has
been shown to be critical for a complete p53 apoptotic response to genotoxic DNAdamaging agents (45). The DBD is located at the central core and binds to consensus
sequences of DNA often in the promoter region of p53 target genes. Mutations in the
DBD account for 90-95% of all p53 mutations, and encompass exons 5-9 (46, 47). Most
of these are single a.a. substitution point mutations and are quite often located at ‘hot
spots’, or frequently mutated spots in p53. Codons 248, 273, and 175 are some of the
most frequently mutated, corresponding to the distribution pattern in other cancers (48).
Transcription of p53 target genes is abrogated 81% of the time by the inability of p53 to
bind to DNA (49). Interestingly, not all p53 mutations are considered to be equal and
depending on their location, some have been shown to possess partial transcriptional
activity (49). Less than 5% of all p53 mutations takes place outside of the DBD and
occurs very rarely in lymphomas (50). Lastly, the C-terminal domain binds to DNA nonspecifically and acts as a sensor to numerous posttranslational modifications. Of note,
additional p53 isoforms do exist and are generated by alternative splicing of transcript
variants.
p53 becomes activated in response to various cellular stresses to elicit multiple
biological responses. Upon activation, p53 primarily acts in a transcription-dependent
manner, forming a tetrameric complex that binds to DNA using its DNA-binding domain
in the nucleus. This transactivates a plethora of target genes that regulate biological
outcomes such as cell cycle, DNA damage and repair, apoptosis, senescence, and
differentiation (51-54). Recent studies have also demonstrated p53 involvement in the
regulation of autophogy, glycolysis, and metastasis (55-57). It can also act in a p53transcription-independent manner in the cytosol to facilitate biological responses such
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as apoptosis via direct action at the level of the mitochondria and autophagy.
Levels of active p53 are tightly regulated, although the precise mechanisms of
this

regulation

are

not

entirely

understood.

Regulatory

pathways

involving

posttranslational modifications are thought to predominantly mediate control over p53
activity and stabilization, some of which are shown in Figure 1.4 (58).
p53 posttranslational modifications determine biological outcome (59, 60). DNA
damage or genotoxic stress can stabilize p53 by inhibiting HDM2 (MDM2 or E3 ubiquitin
ligase)-directed p53 ubiquitination (reviewed below) (61). A variety of DNA-damaging
agents, including UV and ionizing radiation, induce phosphorylation of p53 residues

Figure 1.4 The p53–HDM2 feedback loop. p53 is maintained at low levels by its
negative regulator, HDM2. p53 becomes activated upon various stress signals that
release it from HDM2-mediated inhibition and results in elevated protein levels. Once
released and depending on the severity of stress, p53 is subjected to interaction with
other proteins and posttranslational modifications that can influence the p53-dependent
response. p53 can act in a transcription-dependent manner upregulating target genes to
carry out cellular response or in a transcritption-independent way by acting as a
cytosolic pro-apoptotic facilitator at the mitochondria. Reprinted by permission from
Macmillan Publishers Ltd: Nature Reviews Cancer. (62) Copyright 2009.
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within its N-terminal domain. Phosphorylation reduces p53 affinity for HDM2 and inhibits
the ubiquitination and degradation of p53. ATM (ataxia-telangiectasia mutated kinase) is
also capable of reducing ubiquitination and degradation of p53 by phosphorylating
HDM2 (63). The most studied mode of regulating p53 ubiquitination is that of the p14
tumor suppressor that also to binds to HDM2, preventing HDM2-mediated degradation
of p53 (64). Thus, p53-HDM2 binding is central to the regulation of p53 activity (Figure
1.4).
Clinical significance
Inactivation of p53 promotes lymphomagenesis, although how it functions to
prevent lymphoma remains unclear. Evidence suggests that p53-dependent apoptosis
is required for cellular homeostasis of B cells (65, 66). Moreover, p53 has been shown
to play a role in B cell differentiation. A recent in vivo study demonstrated that wt-p53
was capable of preventing the accumulation of incorrectly differentiating B cells, thereby
suppressing the development of lymphoma (67). More recently, Mcl-1 ubiquitin ligase
E3 (Mule), was shown to be crucial for B lymphocyte development, proliferation,
immune response and homeostasis through a feedback loop with p53 in both normal
and stressful conditions, adding an additional layer of complexity to p53 function in B
cells.
The incidence of p53 mutations varies depending on the lymphoma type, subtype
and stage of disease. Considering that the frequency of p53 mutations in hematological
malignancies as a whole ranges from 5-20 percent (47, 68), lymphomas must share
similar features that are cell-type specific. The p53 pathway is often compromised by
alternative mechanisms. Defects upstream or downstream in the p53 pathway are
typically observed in lymphoma and greatly contribute to the loss of wt-p53 functional
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activity.
Response to radiation and chemotherapeutics is typically mediated through the
induction of apoptosis, which is heavily governed by transcription of pro-apoptotic genes
by p53. Therefore, p53 activation is considered to be favorable to the success of these
treatments. Consequently, inactivation of p53 is often associated with a poor prognosis,
relapse, and chemoresistance (65, 69).
Deletion of 17p, the short arm of chromosome 17, is currently used as an
independent prognostic factor in patients diagnosed with NHL, particularly CLL (70). In
many cases, heterozygous deletion of 17p is thought to correspond with p53 mutations,
although this is now starting to become a topic of debate.
The presence of wt-p53 usually signifies a more favorable prognosis. However,
the biological mechanisms activated by wt-p53 can actually hinder the apoptotic
response and protect the cell, enhancing antioxidant activity or facilitating DNA repair
(66, 71). In wt-p53 lymphocytes where downstream effectors are deregulated, p53
activation has been shown to slow lymphoma progression by prolonged or permanent
cell cycle arrest or senescence rather than apoptosis (72). Recent evidence suggests
that autophagy also contributes to inconsistencies in prognosis in wt-p53 tumors,
although it remains to be determined how exactly p53 functions in autophagy.
Autophagy has just been reported to be cytotoxic as well as cytoprotective and to be
associated with resistance to chemotherapeutic agents in various lymphoma subtypes
(73, 74). It is possible that induction of autophagy by wt-p53 contributes to lymphoma
cell survival contrary to the popular belief that it acts as a precursor- or in a coordinated
effort to induce apoptotic cellular death.
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Therapeutic targeting
The prolific tumor suppressor activity of p53, particularly its apoptotic function,
has gained considerable interest as a potential therapeutic strategy. Although there are
numerous ways to reactivate wt-p53 or restore function to mt-p53, such methods have
not made it far enough into the drug development process to become FDA approved.
Considering the importance of the p53 pathway in the pathogenesis of nearly
every lymphoma subtype, there is a crucial need to expand our understanding of the
role of p53 activation in lymphoma cells. The functional role of activated p53 is variable
and has yet to be fully elucidated. Cell type, posttranslational modifications, as well as
other survival factors may influence the extent of p53 activation. Thus, understanding
the role of p53 in lymphoma will enable enhanced targeting of this ‘guardian of the
genome’ in future therapies.
Proteasomal degradation of targeted substrates
In normal, unstressed cells, p53 protein is present at low levels and has a short
half-life (75). HDM2 (human double minute 2, homolog of murine double minute, or
MDM2) is a RING finger E3-ubiquitin ligase that acts as the predominant negative
regulator of p53. HDM2 is also a transcriptional target gene of p53, creating an
autoregulatory feedback loop that regulates p53 activity and stability (Figure 1.3) (76).
One of the most important functions of HDM2 is its ability to target p53 for proteasomal
degradation by a process called ubiquitination.
Ubiquitin is a highly conserved 8.5 kDa protein composed of 76 amino acids that
is ubiquitously found in all cells in the human body (77). The process of ubiquitination
entails covalent attachment of ubiquitin to any one of seven lysine residues within the
target

protein,

forming

mono-

or

polyubiquitinated

polypeptide

chains

(78).
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Ubiquitination not only provides a specific signal for protein degradation, but also
functions in a degradation-independent manner as well, illustrating that this process is
intricately complex.

This three-step procedure is ATP-dependent and mediated by

enzyme family members E1, E2, and E3 (Figure 1.5). First, ubiquitin is activated in the
presence of ATP and E1 ubiquitin-activating enzyme. The C-terminal carboxy group of
ubiquitin and sulfhydryl group of an E1 cysteine residue form a thioester bond upon
release of AMP (79). Second, ubiquitin is transferred to a cysteine residue of an E2
ubiquitin-conjugating enzyme (Ubc). Third, the ubiquitin-bound E2 Ubc binds to an E3
Figure 1.5 Ubiquitination is an enzymatic
process that plays a role in the ubiquitinproteasome
system.
Ubiquitin
is
catalytically conjugated to proteins by
means of an E3 ubiquitin ligase. HDM2 is
used as an example of a RING finger E3
ubiquitin ligase. (i) Ubiquitin-activating
enzyme, E1, initiates ATP-dependent
catalysis of ubiquitin. (ii) Activated
ubiquitin is transferred to ubiquitinconjugating enzyme, E2. E2 binds to
HDM2 and transfers the ubiquitin moiety
directly to a Lysine residue within the
substrate (in this case, p53) that is also
bound to the HDM2 (iii). The conjugated
substrate is degraded to small amino
acid residues by the 26S proteasome
(iv). Ubiquitin is released and free to be
reused by DUBs (v). Figure and figure
legend are modified and reprinted with
permission from Macmillan Publishers
Ltd: Cell Death and Differentiation (80)
Copyright 2011.

ubiquitin ligase, in this case, HDM2, capable of recognizing specific target proteins. E2
Ubc transfers the activated ubiquitin to the HDM2: target protein (p53) complex, where
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E3 ligase forms an isopeptide bond between glycine 76 of ubiquitin and a lysine residue
of the p53. This process is repeated, in most cases, adding ubiquitin monomers to the
first ubiquitin to form polyubiquitinated chains.

Typically, polyubiquitination is

associated with degradation and the target protein is escorted to the proteasome for
degradation. Far less frequently ubiquitinated proteins are trafficked to the lysosome for
degradation (81). The 26S proteasome is an intracellular protease complex consisting
of a 20S catalytic core and two 19S regulatory subunits and is present in the nucleus
and cytosol of eukaryotic cells (82). Here, the proteasome unfolds and degrades the
protein into various-sized peptide fragments. Ubiquitin monomer units that have been
released are recycled for future use.
Ubiquitination can also be reversed by de-ubiquitinating enzymes (DUB), which
facilitate the removal of ubiquitin from their substrates (83).

The balance of

ubiquitination and deubiquitination modifies enzymatic activity, stabilization, and subcellular localization of signaling proteins (84). One such example is HAUSP/USP7
(herpesvirus-associated ubiquitin-specific protease), which has been shown to deubiquitinate p53 and HDM2 in a concentration-dependent manner (85) and is yet
another critical modulator of p53 stability.
The E3 ubiquitin ligase HDM2
Structure and function of HDM2
The hdm2 gene spans approximately 33kb of genomic DNA and consists of 12
exons. Exons 3-12 encode the coding sequence of full-length HDM2, which display
both tumor suppressive and oncogenic properties. mRNA transcripts can arise from two
different promoters. Transcripts from the P1 promoter in normal, unstressed cells lack
exon 2, whereas the p53-inducible promoter generates transcripts lacking exon 1 (86).
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The predominant HDM2 transcript encodes a protein 491 a.a. in length and is
comprised of an N-terminal domain containing a hydrophobic binding pocket for p53, a
central acidic domain, a putative zinc finger domain, and the C-terminal RING finger
domain (Figure 1.6) HDM2 also contains a NLS, NES, and nucleolar localization signal
(NoLS) (87). Over 40 alternatively spliced transcript variants of HDM2 mRNA have
been identified in a variety of cancers, including lymphoma, and are often found
together with full-length HDM2 transcripts.

Many are also found in normal tissues,

indicating that spliced forms may have normal physiological functions. Little is known

Figure 1.6 Secondary structure of
HDM2, its domains, and its E3
ligase activity. A, Interaction of p53
and HDM2 occurs at the Nterminus where p53 binds to a
pocket within the p53 binding
domain. Also shown is the
ubiquitination
process
and
proteasomal degradation of p53.
B, Autoubiquitination and selfdegratory activity of HDM2.
Addition of ubiquitin moieties
occurs at Lysine residue 466 within
the RING finger domain at the Cterminus.
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about the functions of alternatively spliced HDM2 transcripts and whether they are
translated into protein, since the propensity for alternative splicing could differ from each
promoter as well as their translatability.

Some studies indicate that splice variants

encode proteins that display transforming ability in vitro and in vivo.

However, in

different model systems, these splice variants have been shown to release p53 from
full-length HDM2, acting as tumor suppressors by inducing wt-p53 activity. Alternatively
spliced isoforms may regulate the activity of full-length HDM2 and p53.

The

implications of these isoforms and how their functions are controlled are not well-known
(88-90).
Increased HDM2 protein levels attenuate p53 activity and stability by: 1.) blocking
transcriptional activity of p53 by physically associating with its N-terminal domain; 2.)
exporting p53 out of the nucleus, thereby modulating subcellular localization; and 3.)
ubiquitinating p53, marking it for proteasomal degradation (87, 91, 92). Other negative
regulators of p53 exist, including Cop1, Pirh2, and ARF-BP1, but they are unable to
compensate for the loss of HDM2 (93).
HDM2 is capable of ubiquitinating its own lysine residue 466 and is thought to
degrade itself by means of the proteasome (94, 95).

Although this self-regulatory

function of HDM2 is well-documented, the control and activation of this function still
remains highly elusive. Importantly, HDM2 destabilization is required for proper p53
response. In fact, an early step in the accumulation of p53 in response to stress, DNA
damage in particular, is an associated increase in HDM2 autoubiquitination and
degradation (96, 97).
There is mounting evidence supporting the notion that p53-independent functions
of HDM2 exist through the interaction of HDM2 with additional proteins, which can have
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therapeutic implications.

Their function and significance are not fully understood,

although they have been shown to play a role in cellular responses such as
transcriptional regulation, apoptosis and cell cycle (98, 99).
Expression in lymphoma and clinical significance
Overexpression of HDM2 has been shown to facilitate cancer development and
progression in several tumor types and is often noted in hematological malignancies.
Haploinsufficiency, or a single copy due to deletion or loss of the HDM2 allele inhibits
lymphomagenesis, further supporting the role of its contributing to the development of
lymphoma. In fact, HDM2 was found to be overexpressed in CLL and NHL. Its
expression was found more frequently in low grade NHL (56.5%) compared with
aggressive NHL (10.8%) and more in patients with advanced clinical stage (100).
Abnormal expression of HDM2 has also been shown in HL (101). Little is known about
the prognostic value of HDM2 in lymphomas.
Targeting the UPS for cancer therapy
There is considerable interest in members of the UPS as potential targets for
therapeutic intervention in the treatment of cancer (102-105). The validity of exploiting
the UPS for therapy has been demonstrated by the discovery of the proteasomea34 as
an anticancer target and the development of proteasome inhibitors. Proteasome
inhibitors prevent degradation of polyubiquitinated proteins by inhibiting the proteolytic
activity of the proteasome (106). Considering the ubiquity and essential role of the
proteasome to all cells, it would appear that its inhibition would have profound adverse
side effects. However, increased proteasomal activity is found in highly proliferative
cancer cells compared to normal cells (107, 108), suggesting that these inhibitors may
promote antitumor activity by targeting fast-growing cancer cells. The reason for
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enhanced proteasomal activity in cancer is not understood.
Limitations of Bortezomib
As a single agent, the proteasomal inhibitor bortezomib has demonstrated
preclinical cytotoxic activity in human tumor xenograft models and primary cultures of a
broad spectrum of cancer types (109, 110). It elicits numerous effects on tumor cells
although its predominant mechanism of action is thought to be via interference of the
nuclear translocation of NF-kB and its transcriptional activation (111). However,
proteasomal inhibition also attenuates the degradation of substrates (i.e. p53) that
disrupts the cell cycle and initiates cell death by multiple pathways. Hematological
malignancies, such as lymphomas, appear to be particularly sensitive to the proapoptotic effects of bortezomib.
Several clinical trials have shown promising therapeutic merit in hematological
malignancies. Currently, bortezomib is approved for treatment in multiple myeloma and
mantle cell lymphoma patients (112, 113). Interestingly, not all subtypes of lymphoma
respond to bortezomib. It is plausible that different mechanisms contribute to this
subtype-specific activity of proteasomal inhibition, although the precise mechanisms
underlying this activity are unknown (114, 115).
Bortezomib cannot be considered a targeted therapeutic agent due to its broad
activity. Although the drug was shown to be well-tolerated in many clinical trials while
producing clinical responses, it was still associated with side effects, most commonly
nausea, chronic fatigue, and diarrhea but neutropenia, lymphopenia, hyponatremia,
thrombocytopenia and peripheral neuropathy were also observed (116, 117). Although
many patients do not respond to bortezomib, those that do, eventually develop
resistance, suggesting that there is considerable room for improvement. Targeting
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components of the UPS involved in deregulation of a subset of cellular proteins in a
signaling pathway may offer tumor selectivity while achieving anti-tumor response with
limited toxicity.
Design of SMIs to disrupt p53-HDM2
Physical interaction between HDM2 and p53 occurs at the N-terminal
transactivation domain of p53 and the N-terminal domain of HDM2 (118). More
specifically, 4 key residues (Phe 19, Leu 22, Trp 23, Leu 26) of p53 bind to the
hydrophobic binding pocket of HDM2. This interaction induces a conformational change
in both proteins which may allow other proteins to interact with the structural domains of
either HDM2 or p53 under physiological conditions. Stressful conditions add additional
levels of complexity to HDM2-p53 interactions (99).
The UPS provides additional targets for possible therapeutic intervention
upstream of the proteasome. The importance of the E3 ligase HDM2 in the regulation of
cellular processes, suggests that targeting the UPS to treat lymphomas warrants
investigation. Exploiting the HDM2-p53 interaction in an attempt to restore wt-p53
activity is an attractive therapeutic strategy. Antisense oligonucleotides, peptide
inhibitors, ribozymes and RNA interference have all been used to target cancer cells
(119-122). HDM2 inhibition by antisense oligonucleotides was previously shown to
stimulate p53 and to reduce tumor growth in mouse xenograft models (123, 124).
Unfortunately, it is difficult to utilize such strategies for therapeutic intervention in the
clinic. As a result, nongenotoxic p53 reactivating small-molecule inhibitors (SMIs) have
been developed. SMIs are designed to penetrate the cell membrane and disrupt the
physical interaction of proteins associated with deregulated signaling pathways. They
work by sequestering and blocking overexpressed molecules, or by allowing negatively
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regulated proteins to regain their functional activity. Theoretically, such SMIs should be
highly potent, specific, cell permeable and possess pharmacokinetically feasible profiles
(125). HDM2 SMIs should provide optimal tumor selectivity and target specificity while
limiting toxicity.
Considerable effort has been expended into the development of therapeutic
strategies to disrupt the HDM2-p53 protein-protein interaction to reactivate the
functional activity of wt-p53. Nutlins were the first class of SMI to HDM2 to be reported
(126). They were discovered in a high throughput screening of synthetic chemical
libraries and possess a cis-imidazoline structure. Newer improved generations have
now been formulated. Spiro-oxindoles were discovered using a structure-based de novo
computational design (127). Both classes specifically bind to the p53 binding pocket of
HDM2 by mimicking four key hydrophobic peptide residues in wt-p53. Crystal structure
studies indicate that Trp 23 seems to be the most important residue for the binding of
p53 to HDM2 since it is buried deep inside the hydrophobic binding cleft (128).
However, spiro-oxindoles possess a greater affinity and specificity for HDM2 than cisimidazolines, perhaps due to the differences in the chemical structure that binds to the
HDM2 hydrophobic pocket. Where Nutlins bind to this region using a bromophenol
moiety, spiro-oxindoles mimic the bulky Trp 23 by an indole ring. Homologs of HDM2,
such as HDMX and proteins containing deep hydrophobic pockets, such as Bcl-2 and
Bcl-xl, bind with much weaker affinity to these SMIs, indicating specificity for HDM2.
Along with high potency and specificity, these two classes of SMIs also exhibit
outstanding cell permeability and pharmacokinetic properties (118, 125, 126). Studies
using HDM2 SMIs have generated sufficient data to demonstrate that these inhibitors
can effectively be used to elicit antitumor response. However, the precise mechanisms
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of susceptibility to HDM2 SMI induced cancer cell death are not completely understood.
The extent that HDM2 SMIs influence p53-independent functions of HDM2 remains to
be determined.
Although inhibition of HDM2 acts in a p53 dependent manner, the regulatory
mechanisms mediating this effect are still uncertain. For example, it was initially thought
that HDM2 inhibition completely abrogated all functionality of the protein after release of
p53. HDM2 appears to be capable of retaining its p53-independent functions in the
presence of Nutlin-3, even when p53-dependent activity is the primary effect seen. Of
importance is the E3 ubiquitin ligase activity of HDM2. The effects of HDM2 inhibition on
HDM2 auto-ubiquitination and p53 ubiquitination are currently unknown. Further, the
precise mechanisms regulating the balance of ubiquitination and de-ubiquitination on
protein-protein interactions such as p53 and HDM2 are not entirely well-defined in the
presence of HDM2 SMIs. Elucidating some of these mechanisms can enhance our
understanding of the therapeutic potential and limitations of HDM2 inhibitors in B-cell
lymphoma.
Although preclinical assessment of many HDM2 SMIs has demonstrated great
promise, it is becoming clearer that multiple distinct molecular mechanisms influence
anticancer activity of each agent. Inadequate mechanistic studies will continue to
prevent their successful utilization for therapy. More importantly, novel HDM2 SMIs are
currently under clinical evaluation in phase I studies, demonstrating the significant
impact and clinical relevance of these agents (129).
The UPS, p53 and lymphoma
Deregulation of the UPS is likely to contribute to the pathogenesis of lymphoma.
Inactivating mutations or deletions in the TP53 gene are found in approximately 50% of

25
all cancers. However, this frequency is much lower in hematological malignancies,
particularly indolent lymphomas, accounting for less than 10% of cases at diagnosis
(130). p53 mutations become more prevalent as the disease progresses, indicate poor
prognosis, and predict aggressive disease that is likely to develop chemoresistance
(131, 132). Therefore, tumor cells containing a wt-p53 are typically more sensitive than
those bearing mt-p53. Overall, mutations in p53 are not a common molecular
characteristic driving lymphomagenesis with the exception of disease progression.
The p53 pathway is often compromised by alternative mechanisms. Aberrant
signaling by other defects upstream or downstream in the pathway, such as HDM2
overexpression, is typically observed in lymphoma and greatly contributes to the loss of
wt-p53 functional activity. Targeting components of the UPS, such as HDM2 using
small-molecule inhibitors, to reactivate p53 is as an attractive therapeutic strategy and
lymphomas are an ideal disease model to test this approach.
Specific aims of the study
Aim 1: To determine the biological effect of spiro-oxindole HDM2 inhibitors on B-cell
lymphoma with WT & mutant p53 in vitro & ex vivo.
Aim 2: To examine the involvement of p53-dependent molecular mechanisms upon
inhibition of HDM2 in B-cell lymphoma.
Aim 3: To investigate additional molecular effects of spiro-oxindole HDM2 SMIs on
HDM2 upon physical disruption of HDM2-p53.
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CHAPTER II
MATERIALS AND METHODS
Experimental design
The use of cell lines as a drug screening model is a valuable tool for assessing
preclinical activity of newly developed anticancer agents. However, successful
translation into phase I clinical studies are frequently marred by their questionable
relevance to patient outcomes. Immortalized cell lines may undergo alterations and lose
authenticity of cell and tissue-specific characteristics which complicates the validation of
drug treatments. An advantage of using cell lines is the convenience they provide to
researchers. Cell lines offer a continuous source of cells where multiple independent
experiments can be repeated to verify results. They also provide an opportunity for indepth investigations that could lead to novel mechanistic findings.
Primary cells obtained from patients provide the most physiological relevance
possible. Therefore, access to malignant B lymphocytes derived from lymphoma
patients was of particular importance to this study. This would allow us to compare and
validate results from patient derived cells with those obtained in cell lines. Furthermore,
patient samples also validate the clinical relevance of the cell lines if results are
consistent, particularly when determining mechanisms of action or performing
investigations that cannot be logistically conducted on patient samples. We reasoned
that results from the in vitro cell line data would be similar to the results obtained using
patient samples. However, we are certainly aware of the existence of differences that
may occur between each cell model which must be taken into consideration as well.
Cell lines and culture conditions
WSU-FSCCL, WSU-DLCL2 and WSU-WM were established in our laboratory as
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described previously (133-135). WSU-FSCCL is a human B cell follicular small cleaved
cell line; WSU-DLCL2 is a human diffuse large B cell line, WSU-WM is a human
Waldenstrom’s macroglobulinemia cell line. The human Hodgkin lymphoma cell lines
KM-H2, L-540, and L-591 were obtained from DSMZ (Germany). The human diffuse
lymphoma cell lines RL and Toledo were purchased from the American Type Culture
Collection (Rockville, MD). None of the lymphoma cell lines used was virally
transformed. All cell lines and primary cells were cultured in suspension in RPMI 1640
medium supplemented with 10% fetal bovine serum (Denville) and 1% Penicillin
Streptomycin (Invitrogen) at 37oC and 5% CO2 in a humidified incubator. Cells were
seeded at a density of 2 x105 cells per mL prior to use in functional assays.
Human Investigation Committee (HIC) approval
Prior to conducting research on patient samples, it was mandatory to meet
University and Federal guidelines. Extensive knowledge of protocols for working with
human subjects was required for all personnel involved in the research proposal, and
instruction on this was completed through the Collaborative Institutional Training
Initiatives (CITI) online training module system. Documentation for the proposed
research project was submitted by Angela Sosin to the Wayne State University
Institutional Review Board (IRB) for expedited review and she designated the Principal
Investigator (PI) of the approved study. Patients cells were obtained from the
Lymphoma Clinic at the St. John Hospital Van Elslander Cancer Center under the
direction of Dr. Ayad Al-Katib in accordance with an IRB approved protocol and all
patients had signed informed consent prior to sample procurement. This project was
also reviewed and approved by the IRB at St. John Hospital Van Elslander Cancer
Center as well as the Human Investigation Committee (HIC) at Wayne State University
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School of Medicine (see Appendix A).
Isolation and purification of patient-derived B lymphocytes
Lymphoma tissue was obtained from untreated patients diagnosed with B cell
NHL. Peripheral blood was collected from patients with circulating lymphoma cells, (i.e.
leukemic phase). In both cases, the samples were the remainder of blood or tumor
tissue that have already been drawn or biopsied and had already undergone clinical
testing at St. John Van Elslander Cancer Center. Cells from normal, healthy anonymous
donors were extracted from discarded apheresis cones and/or filters obtained from the
Red Cross and were kindly provided by Dr. Martin Bluth, Associate Director of Detroit
Medical Center Transfusion Services.
The methodology described in this section explains a detailed, highly modified
protocol for the isolation and purification of primary B lymphocytes that produced
consistent results.
Samples collected from the St. John Van Elslander Cancer Center were properly
documented using a coded identifier. Patient-derived and normal donor peripheral blood
mononuclear cells (PBMCs) were isolated using LymphoPrep (ProGen Biotechnik)
density gradient centrifugation (Figure 2.1A). The PBMC fraction contains a mixture of T
cells, B cells, NK cells, basophils, macrophages, monocytes and dendritic cells. Tissue
was minced using steel mesh in a petri dish and the cells resuspended in RPMI media,
and subjected to isolation of mononuclear cells. Peripheral blood drawn from lymphoma
patients was diluted with RPMI media in a ratio of 1:4 (Figure 2.1B). Contents of
apheresis cones from normal donors (Figure 2.2A) were collected in a 15 mL tube
(Figure 2.2B) and diluted 1:9 with RPMI media. Diluted blood was carefully layered in a
1:1 ratio on top of LymphoPrep (Figure 2.1C) to prevent red blood cell (RBC) lysis and

29
centrifuged at 500 x g for 20 minutes. Four distinct layers are present after
centrifugation: the erythrocytes and granulocytes are located at the bottom; the buffy
coat or PBMCs are layered thinly on top of the LymphoPrep layer (Figure 2.1D); and the
top layer is the media containing plasma and platelets. The PBMCs were carefully
collected and transferred to a new 50 mL conical tube (Figure 2.1E), centrifuged at 500
x g for 5 minutes (Figure 2.1E) and, washed with 5 mL of 1X PBS, twice to ensure that
the cells are free of any residual, cytotoxic LymphoPrep.

Figure 2.1. Isolation of PBMCs from a lymphoma patient in leukemic phase. A,
Collection of peripheral blood in a heparin-coated tube. B, Peripheral blood transferred
to a 50 mL conical tube and diluted with RPMI media without FBS. C, Diluted contents
were carefully overlayed in a 1:1 ratio onto LymphoPrep. D, PBMC buffy coat layer after
centrifugation (shown with arrow). E, Removal of PBMC layer and transfer to a new 50
mL conical tube. F, Resultant cell pellet following centrifugation of PBMC buffy coat.
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Figure 2.2 Isolation of normal donor B-lymphocytes from post-leukoreduction apheresis
cones. A, Picture of a discarded apheresis cone. B, Contents were eluted by gravity
flow through prior to dilution and LymphoPrep separation of PBMC’s.

Monocyte Depletion
Cells were resuspended in media and counted on a hemacytometer using
Trypan blue exclusion dye to determine cell number and viability. About 40% of the
isolated mononuclear cells are monocytes and macrophages and adhere to plastic
surfaces, whereas lymphocytes do not. Therefore, resuspended cells were dispensed
into T75 flasks and placed in a 37º incubator for approximately 1-2 hours to allow cells
to adhere to the plastic surface. Cells devoid of monocytes were then collected and
centrifuged at 400 x g for 5 minutes, then resuspended in 1X PBS. An aliquot was
analyzed by FACS.
T Cell Depletion
T cells were depleted from the cell suspension lacking monocytes using 100 µl
pan CD2+ Dynabeads (Dynal), which is necessary for negative selection (depletion) for
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up to ~ 5 x 108 cells. Cells were incubated with prewashed beads for 30 minutes at 4ºC
while rotating. After the T cells were removed using the DynaMag as a magnetic device,
the unbound, negatively selected, highly pure B cell population was removed by
aspiration and an analyzed using FACS to confirm T cell depletion (Children’s Hospital
Flow Cytometry Facility, Detroit, MI). The enhanced, purified B lymphocytes were
subsequently used for functional assays.
Chemical synthesis, reagents, drug treatment, and competitive binding assay
MI-219 (Ascenta Therapeutics) was synthesized using methods published
previously (118, 127). Disulfiram, Nutlin-3 (Sigma Aldrich), its 150-times less active
enantiomer (+)-Nutlin-3b (Cayman Chemical), and MI-319 were dissolved in 100%
DMSO as 10 mM stock solutions. MG132 (Cayman Chemical) and cycloheximide
(Sigma) were dissolved in 100% DMSO as 100 mM stock solutions. Reagents were
diluted to working solutions using sterile water. Fluorescence polarization-based
competitive binding assays were performed to determine the binding affinity of MI-319
and MI-219 with a recombinant His-tagged HDM2 protein. The assays were carried out
as described previously (136).
Cell viability assays
Cells were seeded at a density of 2 x 105 /ml and allowed to adapt overnight
before exposure to increasing concentrations of Nutlin-3, MI-319, or MI-219. Control
cells were treated with equal volume of DMSO for a final concentration of 0.1%. 3-(4, 5dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) reagent (Sigma) was
added 24, 48 or 72 hours later to halt reactions.

Purple formazan crystals were

solubilized in DMSO and absorbance was read in a plate reader at 540 nM. Cell viability
was also determined by a Trypan blue dye exclusion assay using 0.4% Trypan blue
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(Sigma). IC50 was assessed as 50% inhibitory concentration as compared to vehicle
treatment. Data are representative of at least three independent experiments.
Morphology
Cells were exposed to 10 μM Nutlin-3 and MI-219 for 48 hours. For light
microscopic examination, KM-H2 cells were seeded as described above. Briefly,
aliquots from untreated cells (control) and treated cells were cytocentrifuged in a
Cytospin II centrifuge (Shandon Southern Instruments). Cell smears were air-dried,
stained with tetrachrome at full concentration for 5 minutes and then at 50% dilution with
distilled water for another 5 minutes. Slides were analyzed under light microscopy
(Nikon). Features of apoptosis looked for included nuclear chromatin condensation,
formation of membrane blebs, and apoptotic bodies.
p53 sequencing
To sequence the p53 coding region, RNA was extracted from approximately 1
million cells of each patient sample or cell line using a ZR-Duet™ DNA/RNA MiniPrep
kit (Zymogen). The amount of RNA was determined by UV absorption at 260 nm. 1 µg
of each sample was reverse-transcribed using the SuperScript® VILO™ cDNA
synthesis kit per manufacturer's instructions (Invitrogen). 200 ng was used in each
reaction of p53 PCR amplification. Two primer sets were designed and used to amplify
p53 exons 5-9, which encode the DNA-binding region that contains greater than 90% of
all p53 mutations (47). The sequence and characteristics of each primer is listed in
Table 2.1 and have been previously published by our lab (137).
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Table 2.1. p53 primers used for sequencing.
Primer

Sequence of Primer
(5` to 3`)

Strand

Start
Codon

Stop
Codon

Melting
Temperatur
e (Tm in ºC)

% GC
Conte
nt

p53-F1

Sense

AAG TCT AGA GCC ACC GTC CA

61

80

54.33

55

p53-R1

Anti-sense

CAT AGG GCA CCA CCA CAC TA

858

839

53.20

55

p53-F2

Sense

GTG GAA GGA AAT TTG CGT GT

786

805

51.49

45

p53-R2

Anti-sense

GTG GGG AAC AAG AAG TGG AG

1403

1384

52.23

55

The location of these primers in relation to the p53 coding sequence is depicted
in Figure 2.3 along with the primer sets and PCR conditions used to amplify p53 cDNA
in Table 2.2.

Figure 2.3. Location of p53 primers on p53 cDNA.

Table 2.2.p53 primer sets and PCR conditions.
Primer Set

Denaturation
(ºC)

Annealing
(ºC)

Extension
(ºC)

# of Cycles

Product Length
(in bp)

p53-F1/p53-R1

94

52

72

35

798

p53-F2/p53-R2

94

52

72

35

618

Amplified PCR products were analyzed by agarose gel electrophoresis. PCR
products were then cut and purified using Wizard SV Gel/PCR Cleanup kit (Promega).
Two primers, one from each primer set, and 200 ng of PCR product was sequenced by
GeneWiz, Inc. Sequencing was performed on the Applied Biosystems ABI Prism 3730xl
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DNA Analyzer using fluorescent dye terminator detection (Applied Biosystems, CA).
DNA sequences were screened for mutations using BLAST to the p53 coding
sequence: NCBI Reference Sequence: NM_000546.4.
RNA extraction, cDNA preparation and real-time quantitative PCR (qRT-PCR)
Total RNA was extracted from treated lymphoma cells using the PureLink™ RNA
Mini Kit (Invitrogen). Total RNA was quantified by NanoDrop and 1 µg of each sample
was reverse-transcribed using the SuperScript® VILO™ cDNA synthesis kit per
manufacturer's instructions (Invitrogen). The resulting cDNA preparations were then
cleaned of excess enzyme with Wizard SV Gel/PCR Cleanup kit (Promega). qRT-PCR
amplification was conducted in a 10 μl reaction using the Roche LightCycler® 480
SYBR Green I Master (Roche) according to manufacturer’s protocol. 100 ng total RNA
was used for each reaction and mixed with Quanti Tect Primers (Qiagen) to p53, HDM2,
p21, p53AIP1, TIGAR and GAPDH. Reactions were carried out in a 384-well plate using
the LightCycler® 480 System (Roche).
Flow cytometric analysis
Apoptosis
For analysis of drug-induced apoptosis, cells were stained with FITC-conjugated
Annexin V and propidium iodine using the Annexin V/PI kit according to manufacturer’s
protocol (BioVision). Apoptosis was also measured using the TUNEL-based
ApoDIRECT DNA Fragmentation Assay Kit (BioVision). The percentage of apoptotic
cells was quantified using a Coulter EPICS 753 flow cytometer.
Cell cycle
Cell cycle analysis was conducted using flow cytometry of propidium idodide (PI)stained cells. Following exposure of cells to either Nutlin-3 or MI-219 for the specified
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time, cells were harvested, washed and fixed with 75% ice-cold ethanol overnight. Cells
were then stained with PI at a final concentration of 50µg/ml and analyzed on Coulter
EPICS 753 flow cytometer. All in vitro flow cytometric experiments were performed
three independent times. The percentage of cells in G0/G1, S, or G2/M was determined
using a ModFit 5.2 computer program.
Western blots
Cultured cells were collected by centrifugation, washed twice with 1X PBS, and
solubilized in M-PER lysis buffer (ThermoScientific) containing a cocktail of protease
and phosphatase inhibitors (ThermoScientific). The concentration of total cell lysate was
quantified by BCA protein method. 50 µg of total cell lysate proteins were fractionated
onto 14% or 4-20% Tris-Glycine SDS-PAGE gels, transferred onto PVDF membrane,
and probed with primary antibody. Secondary antibodies were anti-mouse or anti-rabbit
conjugated

to

HRP

(Jackson

Immuno).

Proteins

were

visualized

using

chemiluminescence substrate reagent. A list of the antibodies used in this study is
located below in Table 2.3.
Table 2.3 List of antibodies
Antibody

Company

Host

Clonality

p53 (DO-1)
HDM2 (AF1244)
p21 (2974)
Cleaved PARP (5625)
Cleaved Caspase-3 (9664)
Ubiquitin (3936)
His-Tag (27E8)
GAPDH
p53 PAb421
HDM2 (D-12)
Caspase-9 (H-170)
HDM2 (SMP-14)
CyclinD1 (HD11)
LC3A/B (4108)
Caspase-3 (H-60)
Caspase-8 (H-134)
MDR1 (D-11)
Rb (C-2)

Santa Cruz
R & D Systems
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Trevigen
Calbiochem
Santa Cruz
Santa Cruz
Santa Cruz
Santa Cruz
Cell Signaling
Santa Cruz
Santa Cruz
Santa Cruz
Santa Cruz

Mouse
Rabbit
Mouse
Rabbit
Rabbit
Mouse
Mouse
Rabbit
Mouse
Mouse
Rabbit
Mouse
Mouse
Rabbit
Rabbit
Rabbit
Mouse
Mouse

Monoclonal
Polyclonal
Monoclonal
Polyclonal
Polyclonal
Monoclonal
Monoclonal
Polyclonal
Monoclonal
Monoclonal
Polyclonal
Monoclonal
Monoclonal
Polyclonal
Polyclonal
Polyclonal
Monoclonal
Monoclonal
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Immunoprecipitation and co-immunoprecipitation
WSU-FSCCL or KM-H2 cells were treated with Nutlin-3 or MI-219 for specified
periods of time and collected as described above. 1 mg of total cell lysate was
incubated with 5 µg primary antibody overnight (a 1: 1 ratio of HDM2 antibodies SMP-14
and D-12, Santa Cruz) rotating at 4ºC. 30 µl Protein G agarose beads (Millipore) were
added to each sample and incubated at 4ºC for 4 hours. Antibody: antigen complexes
were washed 3 times with PBS prior to the addition of 30 µl SDS-PAGE buffer,
denatured at 95ºC for 5 min, and centrifuged briefly. Immunoprecipitates were then
subjected to SDS-PAGE and probed for protein of interest.
HDM2 autoubiquitination assay
Autoubiquitination assays were performed using 200 ng of recombinant HisHDM2 in the presence or absence of E2-conjugatng enzyme, UbcH5b, recombinant
human E1 (Boston Biochem), and with or without HDM2 SMI. Final concentration of the
drug was IC50 or 50 µM for Nutlin-3, MI-219, and MI-319 diluted in 30 µL reaction
volume. Disulfiram (10 µM) was used as a control. Samples were incubated for 1.5
hours at 30ºC. The reaction was stopped with the addition of 10 µl of 3X SDS loading
dye, boiled for 5 minutes, separated on a 4-20% Tris-Glycine gradient gel (Invitrogen),
and subjected to immunoblotting.
Gel band quantification
ImageJ densitometry software (Version 1.45, US National Institutes of Health;
http://rsbweb.nih.gov/ij/index.html) was used for quantification of Western blot bands from

treated patient samples. Selected bands were quantified based on their relative
integrated intensities, calculated as the product of the selected pixel area and the mean
gray value for those pixels normalized to internal control (GAPDH). Fold increase or
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decrease was calculated by standardizing each treatment as a ratio to the control.
Data and statistical analyses
Statistical analyses were performed by two-way ANOVA unpaired two-tailed
GraphPad Prism v. 4.0 or unpaired two-tailed t test using Microsoft Excel. P<0.05 was
considered significant. Biostatistical guidance and analyses was performed by Dr.
Judith Abrams to verify assumptions, locate outliers, and determine associations.
Relative quantification of mRNA from lymphoma cell lines
Two independent drug treatments per sample were performed in triplicate and
each reaction was repeated once to ensure accuracy. The PCR cycle number at
threshold (CT) was used for the comparison. Baseline gene expression and that after
treatment were quantified by qRT-PCR relative to GAPDH using the Ct method and
expressed as fold induction of gene expression relative to that in the untreated control
(138). Error bars plotted represent mean values ± SE.
Biostatistical analyses of Western blots from patient samples
Relative density was selected as the endpoint. It is defined as the ratio of the
absolute density for a given protein treated with a given drug, at a given concentration,
for a specific time, for a specific patient to the absolute density of GAPDH under the
same conditions. Evaluation of the shape of the frequency distribution of relative density
indicated that a natural log transformation was required to meet the assumptions of the
statistical tests. Fixed effects linear models were used with drugs, Nutlin-3 and MI-219
concentrations, proteins, and time as fixed effects and patient as the random effect.
Holm’s procedure was used to adjust for multiple comparisons.
Biostatistical analyses of tumor cell viability from patient samples
Samples from each patient were treated with Nutlin-3 or MI-219, at 3 different
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concentrations (2.5, 5, and 10µM) for up to 72 hours. There were a minimum of 2 and a
maximum of 6 replications for each patient at each drug, dose, and time point. Cell
survival ranged from 0% to 100%. The quantile-quantile plot indicated that the observed
data had a longer right tail than would be expected if the data were normally distributed.
Nonetheless, a mixed effects analysis of variance was used because the violation was
not outrageously extreme and because no better alternative could be found given the
experimental design. In the mixed effects model drug, concentration and time were
defined as fixed effects; patient and replication were defined as random effects. Holm’s
procedure was used to adjust for multiple comparisons.
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CHAPTER III
BIOLOGICAL EFFECTS OF HDM2 SMIs IN LYMPHOMA CELLS
Introduction
Preclinical assessment of disrupting the p53-HDM2 interaction with Nutlin-3, the
proto-typical HDM2 SMI, has shown promise in a variety of cancer types retaining wtp53 with minimal effects in normal cells. HDM2 SMI inhibition would primarily result in a
p53-dependent response and upregulation of its target genes. Previous studies with
Nutlin-3 have shown that the anti-tumor response is the result of the upregulation of
p53-dependent target genes primarily affecting cell cycle arrest and apoptosis (126).
The precise mechanisms of susceptibility to HDM2 SMI induced cancer cell death are
not completely understood despite extensive data supporting antitumor activity.
Although Nutlins demonstrate ideal characteristics of a nongenotoxic, targeted
therapeutic agent, preliminary data from clinical trials are proving to be less fruitful.
Thus, research on design of additional SMIs and elucidation of molecular mechanisms
has continued. SMIs are believed to penetrate hematological cells such as lymphoma
cells with greater ease than solid tumors. This dissertation seeks to expand upon
existing observations using the novel spiro-oxindole compounds, MI-319 and MI-219,
and lymphoma as a disease model. In particular, lymphomas are an ideal tumor type for
HDM2 inhibition considering the high frequency of wt-p53 and HDM2 overexpression
found in this disease. Further, p53 signaling and its functional consequences are not
fully elucidated in the presence of SMIs in lymphoma cells.
Studies in this chapter were designed to determine the biological effect of MI-319
(initially) and MI-219 on lymphoma cells with wt- and mt-p53 status in vitro and isolated
primary B-lymphocytes ex vivo. These studies also address the involvement of p53-
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dependent molecular mechanisms upon HDM2 inhibition with HDM2 SMIs. Since
apoptosis and cell cycle arrest are the predominant biological responses of p53
activation, it was important to assess well-known key regulators of these processes
upon treatment with HDM2 SMIs, with emphasis on apoptosis. The initial hypotheses for
this portion of the study are as follows: 1) HDM2 inhibition in wt-p53 B-lymphoma cells
will lead to apoptosis and cell-cycle arrest; 2) MI-319 (MI-219) will induce apoptosis in
fresh wt-p53 lymphoma patient samples ex vivo; 3) MI-319 (MI-219) mediates its key
cellular effects by activating the p53 pathway. Results of preclinical assessment of
spiro-oxindoles were compared to Nutlin-3, a cis-imidiazole, as a standard and with the
rationale that both classes of HDM2 SMI would produce parallel observations. These
experiments were designed to delineate p53-dependent responses to HDM2 inhibition
in lymphoma cells with the anticipation of translating HDM2 SMIs to the clinic as a
potentially new therapeutic intervention strategy.
Results
Spiro-oxindole compounds bind to HDM2 protein with high affinity
MI-319 is a laboratory grade spiro-oxindole HDM2 SMI initially used and the
backbone of this study. Some of the growth inhibitory data obtained from this portion of
the study were published in Molecular Cancer in 2009. In this report, the MDM2
appellation of HDM2 was used. The following was taken from: ‘An MDM2 antagonist
(MI-319) restores p53 functions and increases the life span of orally treated follicular
lymphoma bearing animals.’ (Note: this dissertation did not use animals, however, there
was an approved animal protocol in place for using these HDM2 SMIs under the
supervision of Dr. Ramzi Mohammad, one of the co-authors on the publication). The
chemical structure of MI-319 has the same spiro-oxindole structure as MI-219 with the
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addition of a Fluoride group, which enhances the solubility and may increase the affinity
of the compound (Figure 3.1A). The fluorescence polarization-based competitive
binding assay determined that MI-319 binds to recombinant human MDM2 protein with
a Ki value of 9.6 + 3.9 nmol/L, which is lower than the Ki values of 13.3 + 1.8 nmol/L
and 36.0 + 9.0 nmol/L determined for MI-219 (Figure 3.1B) and Nutlin-3 (139),
respectively. Therefore, MI-319 binds to human MDM2 protein with an affinity slightly
higher than that of MI-219 and Nutlin-3. It appeared that both MI-319 and MI-219 were
more than 500 times more potent than the p53 peptide in binding to MDM2 (Figure
3.1B).
Figure
3.1
Chemical
structure of MI-319 and
MI-219 and MDM2 protein
binding
assay.
A,
Chemical structure of MI319 and MI-219. B, MI-319
and
MI-219
binding
affinities (Ki values) as
determined
by
a
competitive fluorescence
polarization-based binding
assay using recombinant
His-tagged MDM2 (amino
acids 1-118) and PMDM6F (5-FAM-βAla-βAla-PheMet-Aib-pTyr-(6-Cl-LTrp)Glu-Ac3c-Leu-Asn-NH2), a
fluorescently labeled highaffinity p53-based peptide.

42
Detection of p53 mutations in lymphoma cell lines
Since wt-p53, but not mt-p53, cells are responsive to HDM2 SMIs, assessment of
the mutational status of TP53 was necessary prior to the preclinical screening of these
agents. Using the primers listed in Table 2.1, the established lymphoma cell lines WSUFSCCL, WSU-DLCL2 and WSU-WM from our lab were first screened for p53 mutations.
Since WSU-FSCCL was the only wt-p53 cell line, a literature search was performed in
pursuit of wt-p53 NHL and mt-p53 cell lines not immortalized by viral transduction.
Toledo and RL were documented to be wt- and mt-p53, respectively; the HL cell lines
KM-H2, L-540 and L-591 were purchased subsequently. Figure 3.2A shows the
amplification of the p53 coding sequence run on a 1% agarose gel from four of the
lymphoma cell lines screened. Primers p53-F1 and p53-R1 produced a PCR product of
798 bps while product size with primers p53-F2 and p53-R2 was 618 bps; the location
of each primer is shown in Figure 3.2B. Bands were excised from the gel, purified and
sequenced in separate reactions using primers p53-F1 and p53-R2. DNA sequencing
and subsequent BLAST to the p53 coding sequence revealed that four lymphoma cell
lines contained p53 point mutations: WSU-DLCL2 had an Arginine (R) to Glutamine (Q)
mutation at codon 248; WSU-WM had an Arginine (R) to Glutamine (Q) mutation at
codon 213; RL had an Alanine (A) to Proline (P) mutation at codon 138; and Toledo had
a mutation at codon 72. What appeared to be a mutation at codon 72 for Toledo, Proline
(P) to Arginine (R), ended up being a single nucleotide polymorphism (SNP). Since
codon 72 SNPs can vary with the degree of apoptotic induction, as was seen in the
growth inhibition assay in the following section, we chose to exclude it for the rest of the
project. Table 3 shows a summary of the lymphoma cell lines and their corresponding
p53 status.
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Figure 3.2 Amplification of p53 in four of the lymphoma cell lines used.
A, The entire coding region of p53 was amplified using two different primer sets. Primer
set F1-R1 amplified a 798 bp product and set F2-R2 produced a size of 618 bp. B,
Location of p53 primers on p53 cDNA.
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Table 3.1. Status of p53 in lymphoma cell lines.

Assessment of the growth inhibitory effect of MI-319 on lymphoma cell lines
The following was published in: ‘An MDM2 antagonist (MI-319) restores p53
functions and increases the life span of orally treated follicular lymphoma bearing
animals.’ Four lymphoma cell lines WSU-FSCCL [representing follicular low grade nonHodgkin’s lymphoma type that is wt-p53]; (b) WSU-WM [representing plasmacytoid type
that is mt-p53]; (c) RL representing diffuse large B-cell lymphoma, mt-p53; (d) WSUDLCL2 [representing diffuse, Intermediate grade non-Hodgkin’s lymphoma mt-p53];
were used since they represent a wide spectrum of B-cell lineage tumors. MTT assay
was used to monitor cell growth upon exposure to HDM2 SMIs. MI-319, MI-219, and
Nutlin-3 inhibited the growth of WSU-FSCCL cells in a dose-dependent manner after 48
hours where the IC50 of each of the SMIs is estimated to be 2.5 µM. The IC50 cannot be
determined in each of the three mt-p53 lymphoma cell lines even up to concentrations
of 20 µM, and demonstrate approximately a 10-fold greater selectivity in wt- over mt-p53
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cells. Interestingly, each of the mt-p53 cell lines responded somewhat differently to
HDM2 SMIs where WSU-DLCL2 appeared to exhibit the weakest response (Figure 3.3).
(Note: I cannot be certain whether or not the WM treated cells display statistical
significance since this was the one cell line that I did not run a MTT assay on and I do
not have access to the raw data to perform statistical analyses. This was run by one of
the co-authors of the manuscript.)

Figure 3.3 Effect of MI-319 on cell viability in vitro. Cells were grown for 48 hours. The
number of viable cells from established tumor cell lines was determined by MTT assay.
Statistical analysis was done using the t test (two tailed) with 95% confidence intervals
between treated and untreated samples. P < 0.05 was used to indicate statistical
significance. Bars, ± SEM.
Additionally, Toledo (p53 P72R) was exposed to increasing concentrations of
Nutlin-3 and MI-319 for 24, 48, and 72 hours. Results were not published in the
aforementioned manuscript. MTT assay was used to measure the growth inhibitory
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effect of HDM2 SMIs on this lymphoma cell line. As in the other mt-p53 cell lines, an
IC50 could not be determined for either Nutlin-3 or MI-319 at doses up to 10 µM, even
though increasing concentrations showed significance compared to control (Figure 3.4).
Data are represented as a line graph for each time point (Figure 3.4A) as well as
graphed in linear scale for both Nutlin-3 and MI-319 (Figure 3.4B). MI-219 was not
assessed in the Toledo cell line because the decision was made to exclude it before MI219 became available.

Figure 3.4 Effect of MI-319 on Toledo cell viability does not show a typical wt-p53
response. The number of viable cells from the Toledo cell line was determined by MTT
assay after exposure to increasing concentration of Nutlin-3 and MI-319 for 24, 48, and
72 hours. Growth inhibition is expressed as a percentage of the control. Data represent
mean ± SE of three independent experiments, each run in duplicate. P < 0.05 was used
to indicate statistical significance which was done using a two-tailed Student t-test
between treated and untreated sample. A, line graphs B, Linear scale graphs.
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HDM2 inhibition reduces cell numbers in wt-p53 lymphoma cell lines
Shortly after initial preclinical screening of MI-319 and publication of the
manuscript, clinical grade MI-219 became readily available. We inferred that the effects
seen after treatment with MI-219 would be similar to those seen with MI-319. The rest of
this dissertation describes the use of MI-219, with the aim of performing a more
comprehensive analysis to elucidate the consequences of p53 reactivation by HDM2
SMIs in lymphoma cells.

Figure 3.5 HDM2 inhibitors reduce cell viability of wt-p53 lymphoma cells. Wt-p53
(WSU-FSCCL; KM-H2) and mt-p53 (WSU-DLCL2; RL) lymphoma cells were treated
with a range of concentrations of MI-219 (top) or Nutlin-3 (bottom) for 24, 48, and 72
hours. Cell viability was measured by MTT assay as a percentage of controls. Data
represent mean ± SE of three independent experiments, each run in duplicate.
Using the effect of HDM2 SMI on cell count in culture as the endpoint, MI-219
(Figure 3.5, top) was more effective in reducing cell numbers compared with Nutlin-3
(Figure 3.5, bottom) in the wt-p53 cell lines, WSU-FSCCL and KM-H2.

Statistical

analysis was performed for each of the cell lines and at each individual time point but is
not shown. An example of statistical significance is shown in Figure 3.6 after a 24 hour
treatment in WSU-FSCCL (A) and KM-H2 cells (B). Although the IC50 at 48 h was
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Figure 3.6 Statistical significance of the ability of HDM2 inhibitors to inhibit wt-p53
lymphoma cellular growth. The same wt-p53 data as in Figure 3.5 graphed at a single
time point for WSU-FSCCL A. Data represented as line graphs. B. The same data is
represented in a linear graph. C. WSU-FSCCL cells were exposed to HDM2 SMIs and
cell viability was measured by Trypan blue exclusion assay. p < 0.05 was used to
indicate statistical significance which was done using a two-tailed Student t-test
between treated and untreated sample. Bars, ± SEM.
similar for both agents in wt-p53 WSU-FSCCL cells (2.5 and 3 µM, respectively), unlike
Nutlin-3 MI-219 treatment led to complete cell elimination by 72 hours at the 5 µM and
10 µM. The IC50 was significantly different in wt-p53 KM-H2 cells (8 µM for Nutlin-3 vs.
3 µM for MI-219) suggesting that Hodgkin lymphoma may be less sensitive to this
treatment modality. There was no significant effect for either agent, however, in the mtp53 cell lines, WSU-DLCL2 and RL, at the concentrations used. Similar results were
obtained using Trypan blue dye exclusion assays and representative graphs are shown
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in Figure 3.6C. Additionally, we were able to conclude that the IC50’s at 48h were
comparable in each of these two assays to monitor cellular growth inhibition. The
inactive enantiomer Nutlin-3b did not exhibit comparable reduction in cell growth, even
at 20 µM, as detected by MTT assay (Figure 3.7). This demonstrates the selectivity of
active HDM2 SMIs in contrast to the inactive Nutlin-3b.

Figure 3.7 Inactive entantiomer of HDM2
inhibitor on lymphoma cell viability.
Treatment with 20 µM of inactive Nutlin3b has no growth inhibitory effects,
demonstrating the selectivity of active
HDM2 SMIs binding to the p53 binding
pocket of HDM2. Bars, ± SEM.

Characteristics of lymphoma patient samples
To extend the findings in lymphoma cell lines, the effects of HDM2 inhibition in a
number of lymphoma patient samples ex vivo was studied. Analyzable tumor samples
obtained from peripheral blood of 13 patients with B-cell lymphoma in leukemic phase
were enriched for peripheral B lymphocytes and exposed to MI-219 or Nutlin-3. Cells
were then analyzed for cell viability, p53 status and selected protein expression. Patient
characteristics are shown in Table 3.2. Eight patients had small lymphocytic lymphoma
(SLL)/chronic lymphocytic leukemia (CLL), 3 had marginal zone lymphoma (MZL), 1
had Follicular lymphoma, and 1 had diffuse large B cell lymphoma (DLBCL). Male:
female ratio was 5: 8; median age was 69 years (range 62-86). Of the 8 SLL/CLL
patients, 6 had 13q- and the remaining 2 had trisomy 12. All patients, except one
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(patient #9) exhibited wt- p53. Patient # 9, with 17p- chromosomal abnormality detected
in 9% of cells also contained a p53 mutation (Lys132Arg). None of the patients were on
active therapy at the time of study although several patients had been previously
treated.
Table 3.2 Comprehensive list of lymphoma patients.

Optimization of patient-derived B lymphocytes
As a starting point ex vivo, the IC25, IC50 and IC100 of each HDM2 SMI determined
in the cell lines was used for the first two patient samples; doses were optimized further
in subsequent samples. Primary lymphoma cells from patient #2, RC102609, show a
time- and concentration-dependent decrease in cell viability (Figure 3.8A) upon
exposure to HDM2 SMIs. Annexin V/PI assay was performed on the remaining primary

51
cells from patient #2 to monitor apoptotic cell death and show only a slight increase in
Annexin V positively stained cells compared to untreated cells after a 24 hour treatment
with Nutlin-3 and MI-219. This did not correspond to the growth inhibitory data as we
had expected since there was not a great difference in treated versus untreated cells
(Figure 3.8B). An unusual number of untreated cells stained positively for Annexin V
whereas Trypan blue did not show similar results for apoptotic cells (data not shown).
Drug concentrations were standardized (2.5, 5, and 10 µM) shortly thereafter for the rest
of the B cells isolated from lymphoma patients.
Figure 3.8 Optimization of
HDM2 inhibitors in primary
lymphoma cells. A, Blymphocytes from patient
RC102609 were treated with
increasing concentrations of
Nutlin-3 or MI-219 for 24, 48,
or 72 hours. Cell counts were
performed in triplicate and
cell viability was determined
by the Trypan blue exclusion
assay as a percentage of the
controls. B, Annexin V/PI
assay was performed on the
remaining cells to test for
apoptosis after 24 h of
treatment. There are no error
bars or statistical analysis as
only
one
independent
experiment
is
illustrated.
Bars, Mean ± SE.

The high number of Annexin V positive cells in the control in patient #2,
RC102609, seemed unusual, so the assay was used once again in B lymphocytes

52
isolated from patient #3, FH032310 after exposure to HDM2 SMIs for 48 hours (Figure
3.9A). Again, total number of Annexin V positively stained cells was quite high in the
untreated control and dose-dependent increases in the number of apoptotic cells was
more difficult to assess. The percentage of early (Figure 3.9D) and late (Figure 3.9C)
apoptotic cells were graphed separately and indicate that MI-219 treated cells appear to
have completed or have just about completed apoptosis at this particular time point.
Only PI-stained cells, indicative of dead cells, were seen after 10 µM MI-219 treatment,
which may explain the reduction of total cells staining positively for Annexin V at the
higher concentrations.

Figure 3.9 Annexin V/PI is not an appropriate assay to represent apoptosis after
exposure of primary lymphoma cells to HDM2 inhibitors. A, B-lymphocytes from patient
FH032310 were treated with increasing standardized concentrations of Nutlin-3 or MI219 for 48 h. B, Total percentage of Annexin V/PI positive cells, including early (D) and
late apoptotic (C) cells detected in the lower right and upper right quadrants of the flow
cytometric results. Data are representative of one independent experiment.
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Figure 3.10 TUNEL/PI
positive cells after exposure
of primary lymphoma cells
to HDM2 SMIs. A, TdT+ B
lymphocytes from patient
#3, FH032310 (MZL), were
treated with increasing
concentrations of Nutlin-3
or MI-219 for 48 h. B, Cell
cycle analysis extrapolated
from the TUNEL/PI data for
patient #3, FH032310. C,
TdT+ B lymphocytes from
patient
#4,
CS052010
(CLL/SLL), were treated
with
increasing
concentrations of Nutlin-3
or MI-219 for 24 h. Data are
representative
of
one
independent experiment.

Primary

lymphoma

cells

from

patient

#3,

FH032310

(MZL),

show

a

concentration-dependent increase in TdT positive cells (Figure 3.10A) upon exposure to
HDM2 SMIs for 48 hours. Apoptosis results, in terms of number of cells differ between
the Annexin V/PI assay and the TUNEL/PI assay. Primary B lymphoma cells show very
little differences in cell cycle arrest between cells treated with HDM2 SMIs and control
(Figure 3.10B), due to the lack of active cell proliferation. Primary lymphoma cells
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isolated from patient #4, CS052010 (CLL/SLL), also show a dose-dependent increase in
TdT positive cells (Figure 3.10A) after treatment with HDM2 SMIs for 24 hours (Figure
3.10C). TUNEL/PI may be a more appropriate assay to use when assessing apoptosis
in patient samples.
FACS analysis in patient-derived B lymphoma cells
In a normal human being, B lymphocytes typically comprise up to 25% and Tcells upwards of 75% of the PBMC cell population. Patient-derived B lymphocytes levels
may be extremely elevated due to the clonal expansion of B-cells driving the disease.
Considering the high percentage of T-cells typical in an individual without lymphoma, it
was postulated that the biological response of primary lymphoma cells may occur from
T, rather than B lymphocytes. At the very least, residual T cells could affect the results
or interpretation of the data. To eliminate this possibility, a T-cell depletion step was
implemented to ascertain that the patient-derived B lymphocyte population is truly as
enriched as it can be. The enhancement of B lymphocytes from two different patient
samples was tested by flow cytometry. Patient #6, VF011311 (SLL/CLL), went from
87.7% CD19+, CD2- B lymphocytes (Figure 3.11A, right) in the non-depleted PBL
(peripheral blood lymphocyte) cellular fraction to 98.7% after T-cell depletion (Figure
3.11A, left). Patient #10, HH110111 (SLL/CLL), went from coexpressing CD19+ CD5+
(CD5+ is abnormally found on SLL/CLL) on 96.3% of non-depleted PBL cells (Figure
3.11B, left) to 99.8% CD19+ CD5+ post T-cell depletion (Figure 3.11B, right). The use
of two different T-cell markers, CD2+ and CD5+, was used to confirm that the depletion
was not specific to a particular T-cell subset fraction.
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Figure 3.11 Flow cytometric assessment
of the purity of patient-derived B
lymphocytes. A, CD19+ primary B
lymphoma cells isolated from patient #6,
VF011311, were enhanced from 87.7%
to 98.7%. B, Pan CD2+ depletion
enhanced CD19+CD5+ coexpressing
cells from 96.3% to 99.8% in patient #10,
HH110111.

FACS analysis in B lymphocytes from normal donors
Consistent T-cell depletion was achieved in normal donors using the optimized
protocol described Chapter II (Figure 3.12). The enhancement of B lymphocytes from
three different normal donors was confirmed by flow cytometric analysis. T cell depletion
in the donors was detected by overall reductions in T cell subsets CD4 and CD8 (Figure
3.12, 1st and 3rd columns). In each of these three normal donors, CD19+ B lymphocytes
were enhanced a minimum of 4 to 6-fold (Figure 3.12, 2nd and 4th columns).
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Figure 3.12 FACS analysis of B lymphocyte purity after pan CD2+ T cell depletion in
normal blood donors. CD19+ primary B lymphocytes isolated from donor #1 were
enhanced more than 4-fold; donors #2 and #3 were enhanced more than 5-fold.

Growth inhibition in primary lymphoma cells
Enriched primary B lymphocytes were analyzed for cell viability and selected
protein expression. To show individual responses to HDM2 SMIs, three patient samples
representing two different types of lymphomas: AN052510 and FH032510 (mantle zone
lymphomas (MZL)) and VF011211 (small lymphocytic lymphoma/chronic lymphocytic
leukemia (SLL/CLL)) were used. Treatment of each patient sample with Nutlin-3 or MI219 caused a time- and dose-dependent growth inhibition as determined by Trypan blue
exclusion (Figure 3.13A). Trypan blue was also used to determine the percentage of
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apoptosis. Apoptosis in patient samples showed time- and dose-dependent increases in
Trypan blue positively stained cells (Figure 3.13B). MI-219 appeared to have a slightly
greater potency in the induction of apoptosis in primary lymphoma cells compared to
Nutlin-3.
Overall, HDM2 SMIs reduce the cell viability of patient lymphoma cells.
Cumulative cell viability results from n=11 patients for each drug, concentration, and
time point is shown in Figure 3.14. Since there were so many variables involved, a
comprehensive biostatistical analysis was performed by Dr. Judith Abrams on 10 of the
11 patient samples to determine whether there were differences between Nutlin-3 and
MI-219 and their effect on cell viability. The mean cell survival along with standard
errors, for each combination of drug, concentration and time is shown in Figure 3.15
and Table 3.3 demonstrating that MI-219 is significantly more effective (p<0.001) at
reducing the cell viability of primary lymphoma cells than Nutlin-3. Of note, the statistics
performed did not allow the control to fit into each of the combinations (below) resulting
in percent survival of less than 100%.
MI-219 versus Control
The percent survival of patient cells treated with MI-219 is significantly lower at
each concentration used compared to untreated control (p<0.001 for 2.5, 5 and 10 µM).
Cell survival averaged 16% lower at 2.5 µM than for control, 32% at 5 µM, and 49% at
10 µM.
Nutlin-3 versus Control
The percent survival of patient cells treated with Nutlin-3 is significantly lower at
each concentration used compared to untreated control (p<0.001 for 2.5, 5 and 10 µM).
Cell survival averaged 10% lower at 2.5 µM than for control, 21% at 5 µM, and 36% at
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10 µM.
MI-219 versus Nutlin-3: Simple Mode
In this type of analysis, the main effects are only of drug and concentration. This
model fits time as a continuous factor and drug and concentration as nominal factors. It
shows that there is a significant difference between each of the drugs (p<0.001) and
that the percent survival of patient cells averaged 10% lower with MI-219 than with
Nutlin-3. During each 24 hour interval, the survival decreases significantly (p<0.001) by
14%.
MI-219 versus Nutlin-3: Complex Mode
In this type of analysis, the main effects are of each drug by concentration tested
against each of the other drug by concentration. During each 24 hour interval, the
survival decreases significantly (p<0.001) by 14%, similar to the simple mode.
Compared to a concentration of MI-219 of 2.5 µM, cell survival at a concentration of 5
µM averages 16% lower and at a concentration of 10 µM averages 33% (both p<0.001).
Cell survival at a concentration of 10 µM is significantly lower (p<0.001) than at a
concentration of 5 µM. Survival with Nutlin-3 averages 12% lower at a concentration of
5 µM and 26% lower at concentration of 10 µM compared to survival at a concentration
of 2.5 µM (both p<0.001). The difference in cell survival between concentrations of 5 µM
and 10 µM is significant (p<0.001). Regardless of concentration, survival is significantly
lower with MI-219 than with Nutlin-3 (p<0.001 for 2.5, 5 and 10 µM).
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Figure 3.13 HDM2 inhibition dose-dependently reduced cell viability and increased
apoptosis in wt-p53 lymphoma patient cells. A, B. B-lymphocytes from patient samples
AN052510, FH032510, and VF011211 were treated with increasing concentrations of
Nutlin-3 or MI-219 for 24, 48, or 72 hours. Cell viability and apoptosis was determined
by the Trypan blue exclusion assay as a percentage of the controls. Cell counts were
performed at minimum in triplicate.
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Figure 3.14 Cumulative time- and dose-dependent reduction of cell viability of primary
B lymphoma cells after HDM2 inhibition. Pooled data from (n=11) patient samples after
24, 48, and 72 hr treatment (n=37 replicates per time point) with increasing
concentrations of MI-219 and Nutlin-3. A, Mean (cumulative) of the raw number of
viable cells. B, Cell viability was measured as a percentage of untreated controls at
each time point. C, Statistical analysis was performed using two-way ANOVA, followed
by Bonferroni and the differences were considered significant when p < 0.05. All results
are expressed as the mean ± S.D.
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Figure 3.15 HDM2 inhibition reduces cell survival in patient-derived lymphoma cells.
Box plots show the percent survival found in primary lymphoma cells isolated from
lymphoma patients (n=11) after increasing concentrations of MI-219 and Nutlin-3
treatment compared to control at the indicated time point as detected by Trypan blue
exclusion assay. There were replicates (n=37) for each patient using each drug, dose,
and time point. Survival is expressed as a percentage of live cells relative to the total
number of cells detected. The horizontal white line in the box represents the median
while the upper and lower lines of the box endorse the 25th and 75th interquartile range
(IQR). The upper- and lower-most lines extend to cover points within 1.5 times the IQR
and circles outside of the lines indicate outliers. A mixed effects analysis of variance
was used where drug, concentration and time were defined as fixed effects; patient and
replication were defined as random effects. Holm’s procedure was used to adjust for
multiple comparisons. MI-219 is statistically more effective at reducing primary
lymphoma cell viability than Nutlin-3 (p<0.001).

Table 3.3 Biostatistical analyses of lymphoma patient samples.
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A dose dependent increase in p53 was seen in patient lymphoma cells after
HDM2 inhibition. Both Nutlin-3 and MI-219 activated p53 resulting in the upregulation of
p53, selected p53 target proteins, and apoptosis markers as visualized by Western blot
(Figure 3.16). Additional proteins were probed for such as Cyclin D1, Rb, and Mdr1 and
these preliminary results will be discussed and further interpreted in Chapter V. Later
time points (48 hours) showed decreased expression presumably due to degradation,
which will be further discussed in Chapter IV (Figure 3.16 A, B). Effects were best
captured after 24 hour exposure of cells to the agents (Figure 3.16 C-F). Exposure to
MI-219 treatment resulted in enhanced expression of p53 protein compared to that
observed with Nutlin-3 at equivalent concentrations in all wt-p53 cells.
ImageJ was used for densitometry and quantification of patient sample Western
blot bands. Relative density was selected as the endpoint for biostatistical analyses that
was performed by Dr. Judith Abrams (Figure 3.17). It is defined as the ratio of the
absolute density, a unitless measure, for a given protein treated with a given drug, at a
given concentration, for a specific time, for a specific patient to the absolute density of
GAPDH under the same conditions.

Evaluation of the shape of the frequency

distribution of relative density indicated that a natural log transformation was required to
meet the assumptions of the statistical tests. When cumulative data for HDM2, p53, and
p21 were pooled together from the each of the patient samples, the relative density of
proteins in MI-219-exposed cells was significantly greater than that of Nutlin-3 (p=0.001)
(Figure 3.17A). Differences in relative density between each of the proteins HDM2, p21
and p53 at both time points were statistically significant at p<0.001 with both p21 and
p53 having lower density than HDM2, and p21 having significantly lower density than
p53 (Figure 3.17C). For p53 protein expression at 24 hours (Figure 3.17C), relative
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density of cells treated with MI-219 is marginally higher than that of cells treated with
Nutlin-3 at a concentration of 2.5 µM (p=0.05), significantly higher at a concentration of
5 µM (p=0.02) and significantly higher at a concentration of 10 µM (p=0.03). Of special
interest is the observation that MI-219, but not Nutlin-3 induced both higher and lower
HDM2 species which were of greater intensity than that observed in wt-p53 cell lines
(discussed below) at the same time period and equal drug concentration

Figure 3.16 HDM2 antagonists activate the p53 pathway and MI-219, but not Nutlin-3,
stimulates HDM2 self-ubiquitination and degradation in primary B lymphocytes. Shown
are Western blots from six out of ten representative patients that had enough cells for
this type of analysis. B lymphocytes were isolated from whole blood, purified, and
treated with increasing concentrations of HDM2 SMIs for 24 or 48 hours. Purified B
lymphocytes isolated from patients #3 (A) and #4 (B) were exposed to HDM2 SMIs for
48 hours. p53 target proteins showed an unexpected reduction in protein expressive
levels at this time point. C-F, Treatment for 24 hours (patients #3-13; #5 did not have
enough cells for protein analysis) was found to be the optimal exposure time to HDM2
SMIs for patient samples.
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Figure 3.17 Upregulation of p53 protein predicts efficacy and biological response to MI219 in primary lymphoma cells. Box plots show the cumulative biostatistical analyses of
p53 target protein expression levels to estimate response predictors to HDM2
antagonists in primary B lymphocytes isolated from lymphoma patients (n=10). Western
blots for each patient (n=10) for each drug, dose, and time point for each protein
detected. Quantification of Western blot bands (relative density) was calculated using
ImageJ and normalized to internal control (GAPDH). A, MI-219 is statistically more
effective than Nutlin-3 (p=0.001) overall regardless of p53 target protein or time point. B,
Differences in the upregulation of protein expression as a function of relative density
between each of the proteins HDM2, p21 and p53 at both time points combined. HDM2
protein expression is significantly higher than both p21 (p<0.001) and p53 (p<0.001).
p53 protein expression is significantly higher than p21 (p<0.001). C, For p53 protein
expression at 24 hours, relative density of cells treated with MI-219 is marginally higher
than that of cells treated with Nutlin-3 at a concentration of 2.5 µM (p=0.05),
significantly higher at a concentration of 5 µM (p=0.02) and significantly higher at a
concentration of 10 µM (p=0.03). The differences between drugs under all other
combinations of experimental conditions are not statistically significant (all p>0.50). The
horizontal white line in the box represents the median while the upper and lower lines of
the box endorse the 25th and 75th interquartile range (IQR). The upper- and lower-most
lines extend to cover points within 1.5 times the IQR and circles outside of the lines
indicate outliers. Fixed effects linear models were used to monitor relative density as an
endpoint where HDM2 SMIs, concentrations, proteins, and time were defined as fixed
effects; patient was defined as the random effect. Holm’s procedure was used to adjust
for multiple comparisons.
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Similarly, there was also no significant effect on normal peripheral blood
lymphocytes (PBL) isolated from healthy donors (Figure 3.18A). Furthermore, Western
blot analysis showed that HDM2 SMIs have little effect on p53 protein and its targets in
normal B lymphocytes after 24 hours of treatment (Figure 3.18B). Induction of apoptosis
was detected only upon exposure to 500 nM of Doxorubicin. The biological responses
observed post-drug treatment can be attributed to B lymphocytes as flow cytometry
confirmed the enhancement of the CD19+ B lymphocyte population, minimizing the
chance of response occurring from the T cells.

Figure 3.18 Lack of effect of HDM2 SMIs on the cell viability of peripheral B
lymphocytes from normal blood donors. A, Normal B lymphocytes derived from three
(n=3) different donors were exposed to increasing concentrations of Nutlin-3 or MI-219
for 24 and 48 hours. Cell viability was measured by Trypan Blue exclusion assay as a
percentage of controls. Data represent three independent treatments with duplicate
readings. No detection of significance as determined by unpaired Student t-test. B,
Primary B lymphocytes from two of the normal donors were exposed to HDM2 SMIs for
24 hours. Western blot was used to detect p53 target proteins. Bars, Mean ± SE.
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Evaluation of the induction of p53-dependent apoptosis and cell cycle arrest
To clarify the mechanisms of growth inhibition upon HDM2 antagonism, a series
of experiments examining key apoptotic and cell cycle regulators was performed.
Annexin V/PI and TUNEL/PI staining were used to assess drug-induced apoptosis in
each cell line. Wt-p53 WSU-FSCCL cells demonstrated a dose-dependent increase in
Annexin V positively stained cells (Figure 3.19A). Apoptosis primarily occurred after the
first 24h of treatment, as the percentage of Annexin V positive cells did not drastically
increase over time. Interestingly, however, the percentage of Annexin V stained cells
varied dramatically between Nutlin-3 and MI-219 at the same dose, where Nutlin-3
induced far less apoptosis than MI-219. Wt-p53 KM-H2 cells showed a similar pattern of
dose-dependent increases in Annexin V positive cells, although to a lesser extent than
WSU-FSCCL. Mt-p53 WSU-DLCL2 cells did not demonstrate an increase in Annexin V
positively stained cells at any time point with either Nutlin-3 or MI-219, even at the
highest concentration (Figure 3.19B). Due to technical difficulties, we were not able to
analyze Annexin V/PI in RL cells but apoptotic TdT+ cells were detected by the
TUNEL/PI assay.
Cell cycle analysis after 24 h treatment demonstrates that Nutlin-3 treatment
arrests wt-p53 WSU-FSCCL and KM-H2 cells at G0/G1 and G2/M (Figure 3.19C, top).
There is a greater proportion of G0/G1 cells with MI-219 treatment, but this is likely due
to apoptotic cells falling off into G0 and indicates that MI-219 induces cell cycle arrest as
well as apoptosis. Cell cycle arrest is not affected in mt-p53 WSU-DLCL2 or RL cells
(Figure 3.19C, bottom). Taken together, these results demonstrate that both Nutlin-3
and MI-219 induce a cell cycle arrest, but Nutlin-3 to a lesser extent than MI-219, and
the accumulation of G0/G1 arrest is most likely apoptotic cells. TdT+ cells would be the
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best way to help distinguish between true cell cycle arrest and accumulation of cells in
this phase due to apoptosis.

Figure 3.19 Biological response of lymphoma cell lines to HDM2 SMIs. The percentage
of Annexin V positive cells is measured upon exposure to HDM2 SMIs after 12, 24, and
48 hours in wt-p53 (A.) and mt-p53 (B.) lymphoma cell lines. C. Cell-cycle analysis in
wt- and mt-p53 lymphoma cells after 24 hours of HDM2 inhibition. Results are the mean
of at least three independent experiments. Statistical analysis for Annexin V/PI was
performed using two-tailed Student t-test between treated and untreated sample per
time point and the differences were considered significant when p < 0.05. Bars, SEM.
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Table 3.4 Cell cycle arrest p values.

TUNEL/PI was also used to as another experimental method to confirm the
Annexin V/PI results after a 24 hour treatment. Weak TdT positive staining was
detected at all concentrations of Nutlin-3 in wt-p53 WSU-FSCCL cells (Figure 3.20). In
contrast, dose dependent TdT positive cells were seen upon treatment with MI-219,
indicative of cells undergoing drug-induced apoptosis, Nutlin-3 to a lesser extent. The
levels of apoptotic cells appeared to vary between each of the assays although the
difference between each of the two HDM2 SMIs was still apparent. Mt-p53 WSU-DLCL2
and RL cells did not display TdT positive staining with either SMI at any concentration.
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Figure 3.20 Assessment of apoptosis after HDM2 inhibition in lymphoma cell lines.
HDM2 inhibitors activate the apoptotic pathway in WSU-FSCCL, but not WSU-DLCL2 or
RL cells. The percentage of TdT+ positive cells is measured upon exposure to HDM2
SMIs after 24 hours. No statistical significance in mt-p53 lymphoma cell lines WSUDLCL2 and RL. Results are the mean of three independent experiments. Bars, SEM.
To clarify the discordance between apoptosis assays, levels of caspase-3 and
PARP cleavage, indicators of apoptosis, were further tested. Cleavage of caspase-3
and PARP was detected in a dose-dependent manner at each of the time points in wtp53 WSU-FSCCL with evidence of greater induction of apoptosis with MI-219 treatment
than with Nutlin-3 (Figure 3.21). Moreover, caspase-3 and PARP cleavage corresponds
with the results obtained from TdT positive staining more than results from Annexin V/PI
staining. The requirement for functional p53 activity is further confirmed by the lack of
activity seen in mt-p53 lymphoma cells. Overall, these data indicate that HDM2
antagonists promote the reactivity of wt-, but not mt-, p53 in lymphoma cells.

Figure 3.21 MI-219 induces greater apoptosis than Nutlin-3 in wt-p53 WSU-FSCCL
cells. Cleavage of PARP and caspase-3, two indicators of apoptosis, was detected by
Western blot analysis after 12, 24, and 48 hours of exposure to HDM2 SMIs. GAPDH
was used as a loading control.
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Evaluation of p53 protein and p53 target proteins
Activation of the p53 pathway results in upregulation of p53-target proteins and
genes. In order to characterize p53 activation, p53 protein levels and its selected targets
were analyzed. Wt-p53 WSU-FSCCL and KM-H2 cells (Figure 3.22, top half) showed
dose-dependent increases in p53 as well as its targets HDM2 and p21 in treated cells
compared to vehicle control treated cells. Differences in the kinetics of protein
expression between Nutlin-3 and MI-219 were observed. Effects were evident 12 to 48
hours after exposure to HDM2 SMIs. Upregulation of protein expression was greatest
with MI-219 treatment, compared to Nutlin-3 treated cells. Interestingly, HDM2
expression in WSU-FSCCL at 48 hours appeared to Mt-p53 RL and WSU-DLCL2 cells
(Figure 3.22, bottom half) showed slightly elevated levels in HDM2 and p53 protein
levels upon HDM2 inhibition. However, levels of p21 protein were barely detectable
upon HDM2 inhibition. This suggests that the slight increase is likely p53-independent.
These data indicate that wt-p53 lymphoma cells, but not mt-p53, are sensitive to HDM2
SMIs.
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Figure 3.22 Kinetics of p53 reactivation upregulates p53 and its targets upon HDM2
inhibition in lymphoma cell lines. Wt- and mt-p53 lymphoma cell lines were treated with
increasing concentrations of Nutlin-3 or MI-219 for 12, 24, and 48 hours and the levels
of p53-target proteins were assessed by Western blot analysis.

HDM2 inhibition upregulates p53-dependent genes in wt-p53 lymphoma cell lines
To investigate the effects of HDM2 inhibition on p53 transcriptional regulation, we
assessed the effect of SMI-mediated reactivity of p53 to enhance target gene
expression levels (Figure 3.23). Wt-p53 WSU-FSCCL cells exhibited increases in p53target genes HDM2, p21, p53AIP1 and TIGAR (TP53-induced glycolysis and apoptosis
regulator) upon HDM2 inhibition compared to control cells albeit with variable kinetics
(Figure 3.23). Overall, MI-219 treatment demonstrated a surprisingly greater induction
of p53-target genes compared to Nutlin-3. There was much higher and more sustained
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induction of HDM2 mRNA by MI-219 compared with Nutlin-3. Effect on HDM2 transcript
peaked at 12 hours but was still remarkable at 24 hour in MI-219-treated cells. Both
agents induced upregulation of p21 mRNA in WSU-FSCCL cells with overall higher
induction by Nutlin-3 compared with MI-219. However, MI-219 effect was more evident
at the earlier time points (12 and 24 hours) and at lower concentrations (2.5 and 5µM)
compared with Nutlin-3. The later induced a delayed induction (48 hours) of p21mRNA.
MI-219 was more effective than Nutlin-3 in inducing p53AIP1 mRNA. Induction of
TIGAR was relatively unaffected by MI-219, except transiently by high concentration
(10µM) at 12 hour, whereas Nutlin-3 induced delayed (48 hour) but significant increase
in TIGAR Taken together, these findings indicate MI-219 is more effective in inducing
apoptosis than Nutlin-3 and Nutlin-3 treated cells may cause cells to go into senescence
with the upregulation of TIGAR. There were no significant changes induced by either
agent on any of the genes tested in the mt-p53 RL cells. The data are comparable with
the upregulation in p53-dependent target protein levels in Figure 3.22, with the
exception of p21, which may be degraded by HDM2, but was not tested in this study.

73

Figure 3.23 Effect of HDM2 inhibition on p53-dependent gene expression. mRNA
expression levels upon exposure to HDM2 SMIs in WSU-FSCCL and RL cells for the
times indicated. Baseline gene expression and that after treatment were quantified by
qRT-PCR relative to GAPDH using the Ct method and expressed as fold induction of
gene expression relative to that in the untreated control. Error bars plotted represent
mean values ± SE performed in triplicate from two independently treated experiments.
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HDM2 inhibition enhances p53 stability at the posttranslational level
HDM2 inhibition is hypothesized to increase p53 stability by reducing HDM2mediated degradation. However, p53 stability could also be the result of enhanced p53
protein translation. To demonstrate that upregulation of p53 protein expression shown in
the Western blots were the result of HDM2 inhibition by SMIs, the half-life of p53 was
monitored. The inhibition of protein synthesis by treatment with 50 µM cycloheximide
alone led to a marked decrease of p53 protein expression over time (Figure 3.24A).
Furthermore, addition of 10 µM of the proteasome inhibitor MG132 alone (Figure 3.24B)
ameliorates the degradation of p53, thereby enhancing its stabilization. Whether p53
stability is related to HDM2 inhibition was evaluated by pre-incubation of 10 µM Nutlin-3
or MI-219 for 24 hours in wt-p53 WSU-FSCCL cells followed by treatment with 50 µM
CHX at the indicated time points. Blocking protein synthesis while concurrently treating
with HDM2 SMI led to an overall increase in p53 protein expression (Figure 3.24C, D).
Intriguingly, MI-219 treatment was more effective in enhancing p53 stability than that of
Nutlin-3. Furthermore, these results indicate that the increase of p53 protein is not due
to an upregulation of p53 mRNA (Figure 3.24E) at earlier time points. Although we did
not test for a drug washout, it appears that the HDM2 SMIs, particularly MI-219, may be
bound to HDM2 for somewhere between 24-48 hours. p53 mRNA after 48h of treatment
appears to begin transcription of itself suggesting that the HDM2-p53 feedback loop has
normalized.
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Figure 3.24 MI-219 enhances the stability of p53 to a greater extent than Nutlin-3. A, B.
Treatment of wt-p53 WSU-FSCCL cells with 50 µM cycloheximide decreases the halflife of endogenous p53 over time. Similarly, blocking the proteasome by treatment with
10 µM MG132 increased p53 protein stability. Relative density of each band was
measured and normalized to GAPDH. C, D. WSU-FSCCL cells were treated with 10 µM
of Nutlin-3 or MI-219 for 24 hours prior to the addition of 50 µM cycloheximide for the
indicated time points. p53 protein levels were detected by Western blot. E, p53 protein
stability is not a result of mRNA translation into protein at early time points.
Next, we studied the direct effect of HDM2 inhibition on the disruption of the
endogenous HDM2-p53 interaction in WSU-FSCCL cells, since this may be important to
our understanding of the biological outcome. In WSU-FSCCL cells treated for 4 h, the
amount of HDM2 associated with p53 is reduced with increasing drug concentration.
However, it is interesting to note that MI-219 appeared to prevent the association of
HDM2-p53 greater than Nutlin-3. 10 µM MG132 was used as a positive control, as it
does not prevent dissociation, and normal mouse IgG used as a negative control.
Furthermore, whole cell lysate (WCL) input indicates that the presence of p53 is
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Figure 3.25 HDM2 inhibition results in disruption of the HDM2-p53 protein-protein
interaction. A, B WSU-FSCCL and KM-H2 cells were treated for 4 hours with increasing
concentrations of Nutlin-3 or MI-219. Addition of 10 µM MG132 to cells was used as a
positive control. Cell lysates were immunoprecipitated with anti-p53 (DO-1 for WSUFSCCL), anti-p53 (pAb421 for KM-H2), or normal mouse serum (IgG). The
immunoprecipitates were analyzed by immunoblotting against antibodies to HDM2
(AF1244). 10% of WSU-FSCCL total cell lysate was used for input. C, D WSU-FSCCL
cells were treated for 12 hours with increasing concentrations of Nutlin-3 and MI-219.
The blots were probed for the protein that was immunoprecipitated.
detectable in the control. Increasing levels of both HDM2 and p53 are seen, indicative of
enhanced p53 stabilization in the presence of HDM2 SMI. The WSU-FSCCL co-IP
caused a few issues because of the antibody used. p53 DO-1 binds to the N-terminus
where HDM2 also binds and making it difficult to pulldown endogenous p53, let alone
bound to HDM2 as shown in Figure 3.25C. The KM-H2 co-IP uses a different p53
antibody that recognizes the C-terminus of p53 and this blot demonstrates clearly that
p53 and HDM2 are physically interacting in control and MG132 treated cells as
indicated by the proteins located at the molecular weights of HDM2 and p53, but are
absent in the Nutlin-3 and MI-219 treated cells (Figure 3.25B).
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HDM2 SMIs demonstrate differential effects on wt-p53 lymphoma cells
A comprehensive profile of the kinetics of wt-p53 lymphoma cells over the course
of 72 h treatment with HDM2 SMIs shows that both agents arrest wt-p53 WSU-FSCCL
and KM-H2 cells at G0/G1 in a time- and dose-dependent manner (Figure 3.26).
However, KM-H2 appears to arrest some cells in G2/M as well, albeit to a lesser extent.

Figure 3.26 HDM2 inhibition causes cell cycle arrest in wt-p53 lymphoma cell lines.
WSU-FSCCL and KM-H2 demonstrate time- and dose-dependent cell cycle arrest in
G0/G1, and to a lesser extent, in G2/M. Error bars represent SEM of three independent
experiments.

Considering the growth of both wt-p53 cell lines was inhibited and showed cell
cycle arrest, it was surprising to detect apoptosis in WSU-FSCCL, but not in KM-H2.
Particularly when the Annexin V/PI data indicate increases in Annexin V+ cells in a timeand dose-dependent manner (Figure 3.27A). When the TUNEL/PI assay was
implemented, KM-H2 cells did not demonstrate time- or dose-dependent increases in
TdT+ cells (Figure 3.27B), suggesting a lack of apoptosis. p53-dependent target genes
were assessed after exposure to 10 µM MI-219 and Nutlin-3 for 12, 24, and 48 hours
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(Figure 3.27C). Interestingly, the kinetics of upregulation varied between WSU-FSCCL
and KM-H2, but more importantly, HDM2 SMIs did not upregulate p53AIP1 mRNA, also
indicating that KM-H2 cells were not undergoing cell death upon treatment.

Figure 3.27 HDM2 inhibition induces apoptosis in WSU-FSCCL, but not KM-H2
lymphoma cells. A., B. The percentage of Annexin V and TdT positive cells is measured
upon exposure to MDM2 SMIs over time. Results are the mean of at least two
independent experiments. Bars, SEM. C. mRNA expression levels in response to HDM2
SMIs in WSU-FSCCL and KM-H2 cells for the times indicated. Baseline gene
expression and that after treatment were quantified by qRT-PCR relative to GAPDH
using the Ct method and expressed as fold induction of gene expression relative to
that in the untreated control. Error bars plotted represent mean values ± SE performed
in triplicate from two independently treated experiments.
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When KM-H2 cells were immunoblot for apoptosis proteins, there was no PARP,
caspase-3, or even caspase-9 cleavage after 24 hours of exposure to HDM2 SMIs
compared to WSU-FSCCL wt-p53 lymphoma cells (Fgure 3.28A, B). Tetrachrome
staining of KM-H2 cells after 48 hours after treatment with 10 µM Nutlin-3 and MI-219
showed indicators of apoptosis such as membrane blebbing, but no chromatin
fragmentation or breakdown of nuclear membrane (Figure 3.28C). Visually, KM-H2 cells
are not apoptotic and the membrane blebbing indicates that the Annexin V/PI assay
detected false positive apoptotic cells and that Annexin V bound to phosphatidylserine
of the membrane simply because the membrane was compromised.

Figure 3.28 KM-H2 does not undergo apoptosis upon exposure to HDM2 SMIs. A., B.
Cleavage of PARP, caspase-3, and caspase-9, three indicators of apoptosis, were
evaluated by Western blot analysis after 24 hours of exposure to HDM2 SMIs. GAPDH
was used as a loading control. C, Tetrachrome staining of KM-H2 cells as visualized by
light microscopy after a 48 hour treatment.
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It is not clear from these data whether lack of apoptosis in KM-H2 is cell line
specific or applicable to all Hodgkin lymphomas. The discrepancy that was noted
between the wt-p53 lymphoma cell lines prompted screening of Nutlin-3 and MI-219 in
additional HL cell lines, L-540 and L-591. Such analyses would allow for distinguishing
whether or not our observations is specific to the KM-H2 cell line or whether this is
disease specific.
HDM2 SMIs reduce the growth of wt-p53 HL cell lines, albeit at higher concentrations
HL cell lines L-540 and L-591 (both wt-p53) were exposed to increasing
concentrations of Nutlin-3 and MI-319 for 24, 48, and 72 hours as previously discussed.
Trypan blue exclusion assay was used to measure the growth inhibitory effect of HDM2
SMIs. Similar to the other wt-p53 cell lines, L-540 and L-591 were responsive to HDM2
inhibition and IC50 for Nutlin-3 and MI-219. However, whereas each HDM2 inhibitor
showed different IC50’s in KM-H2, they show similar IC50’s in L-540 and L-591 after 48
hours (Figure 3.29, middle pannels). Data are represented as a line graph for each time
point (Figure 3.4A) as well as graphed in linear scale for both Nutlin-3 and MI-319
(Figure 3.4B). The IC50’s in each of the three wt-p53 HL cell lines is much higher than
the IC50 in WSU-FSCCL, suggesting that HL cells may be inherently more resistant to
HDM2 inhibition than NHL cells.
The biological effects of HL cells were investigated upon exposure to HDM2
SMIs. Similar to WSU-FSCCL wt-p53 cells, both L-540 and L-591 showed increases in
Annexin V+ and TdT+ cells upon exposure to MI-219 (Figure 3.30). Nutlin-3 also
showed dose-dependent increases in apoptotic cells, except it was much less
compared to MI-219.
To ensure that HL cells, particularly KM-H2, were capable of undergoing
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conventional apoptosis, they were exposed to proteasome inhibitor and doxorubicin, a
DNA-damaging agent along with HDM2 SMIs and probed for apoptosis markers. MI-219
showed higher molecular weight forms of HDM2 similar to that seen in WSU-FSCCL
and in patient samples. Also, HL cell lines appeared to be more resistant to HDM2
inhibition compared to wt-p53 cell line WSU-FSCCL. KM-H2 was able to undergo
conventional apoptosis with exposure to doxorubicin and MG132, as detected by PARP
cleavage (Figure 3.31).

Figure 3.29 HDM2 SMIs reduce cell growth of wt-p53 HL cells. Wt-p53 (L-540, top; L591, bottom) HL cells were treated with a range of concentrations of MI-219 and Nutlin3 for 24, 48, and 72 hours. Cell viability was measured by Trypan blue exclusion assay
as a percentage of controls. Data represent three independent experiments, with
quadruplicate readings. Bars, ± SEM.
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Figure 3.30 Biological effects of HL cell lines to HDM2 SMIs after a 24 hour treatment.
The percentage of Annexin V positive cells is measured upon exposure to HDM2 SMIs
after 12, 24, and 48 hours in wt-p53 (A.) and mt-p53 (B.) lymphoma cell lines. C. Cellcycle analysis in wt- and mt-p53 lymphoma cells after 24 hours of HDM2 inhibition.
Results are the mean of at least three independent experiments. Statistical analysis for
Annexin V/PI was performed using two-tailed Student t-test between treated and
untreated sample per time point and the differences were considered significant
when p < 0.05. Bars, SEM.

Figure 3.31 HDM2 antagonism in HL cell lines reactivates wt-p53, but are resistant to
p53-induced apoptosis. p53, p53-dependent targets, and apoptosis mediators were
detected by Western blot analysis after 24 hours of exposure to HDM2 SMIs in wt-p53
KM-H2 (A), L-591 (B), and L-540 (C) HL cells. GAPDH was used as a loading control.
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Summary
The following data in Chapter III demonstrates that exposure of lymphoma cells
to HDM2 SMIs results in the restoration of wt-p53 tumor suppressor activity by
disrupting the HDM2-p53 interaction. By means of an in vitro and ex vivo approach,
HDM2 inhibition was shown to reduce cell growth and result primarily in biological
responses of cell cycle arrest and apoptosis. Both agents disrupted the HDM2-p53
protein-protein interaction and stabilized p53 protein by minimizing HDM2-mediated
degradation. Furthermore, the data unexpectedly reveals that MI-219 elicits a
statistically significant difference in potency compared to the well-studied Nutlin-3. The
results from the primary lymphoma cells are consistent with the results from the wt-p53
lymphoma cell lines. This suggests that Nutlin-3 primarily induces a cell cycle arrest,
whereas MI-219 induces apoptosis, as the primary growth inhibitory effect in lymphoma
cells. The surprising existence of significant quantitative and qualitative differences
between effects of two different classes of HDM2 SMIs: Nutlin-3 and MI-219 indicates
that the p53-HDM2 interaction and methods of its disruption are more complex than is
currently realized.
HDM2 antagonism produces distinct biological responses in wt-p53 lymphoma
cells, adding to the complexity of the expected outcome from a wt-p53 response.
Although HDM2 SMIs demonstrate activity in wt-p53 Hodgkin lymphoma (HL) cells, p53
activation alone does not appear to be sufficient for the induction of apoptosis. These
results demonstrate that HL cells may be inherently more resistant to apoptosis
compared to NHL cells. Differences in sensitivity between HL and NHL are not currently
known. The data prompts speculation that the mechanisms underlying drug-induced
apoptosis involve additional molecular determinants which need to be further studied.
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More in-depth understanding of the consequences of HDM2-p53 disruption by SMIs will
aid in maximizing their therapeutic exploitation.
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CHAPTER IV
NOVEL MECHANISM OF ACTION FOR MI-219
Introduction
Ubiquitination is one process that can impact the functional activity of wt-p53
once it is released from HDM2, and the blocking of the p53-HDM2 interaction is thought
to be the mechanism of action of Nutlin-3. Although HDM2 inhibition demonstrates
efficacy in tumor cells in a p53-dependent manner, the regulatory mechanisms
mediating this effect are still relatively uncertain. The mechanism of action of Nutlins is
thought to block the p53-HDM2 interaction but may not interfere with other functions of
HDM2, such as its ubiquitin ligase activity (140). Studies using HDM2 SMIs have
generated sufficient data to demonstrate that these inhibitors can effectively be used to
elicit antitumor response. However, the precise mechanisms of susceptibility to HDM2
SMI induced cancer cell death are not completely understood. The extent that HDM2
SMIs influence p53-independent functions of HDM2 remains to be determined.
For example, it was initially thought that HDM2 inhibition completely abrogated all
functionality of the protein after release of p53. Studies using Nutlins show that HDM2
is capable of retaining its p53-independent functions, even when p53-dependent activity
is the primary effect seen. Of importance is the E3 ubiquitin ligase activity of HDM2.
The regulation of HDM2 auto-ubiquitination and ubiquitination of p53 in the presence of
an HDM2 inhibitor to the p53 binding domain are currently unknown.

The precise

mechanisms regulating the balance of ubiquitination and de-ubiquitination on proteinprotein interactions such as p53 and HDM2 are not entirely well-defined. Elucidating
some of these mechanisms can enhance our understanding of the therapeutic potential
and limitations HDM2 inhibitors in B-cell lymphoma. Results from this chapter were in

86
part to investigate additional molecular effects of MI-319 (MI-219) on HDM2 upon
physical disruption of HDM2-p53. In addition, they aid in the development of a
retrospective hypothesis when parts of data from Chapter 3 were re-analyzed.
Results
The functionality of HDM2 E3 ubiquitin ligase activity in the presence of HDM2 SMIs
One of the pitfalls to HDM2 SMIs is the upregulation of HDM2 since it is a direct
target of p53 due to the negative feedback loop. Our data shows a tremendous amount
of HDM2 mRNA being produced, especially in the presence of MI-219 (Figure 3.23).
One of the caveats to using HDM2 SMIs is that the high HDM2 levels can negate
effects of newly released p53. This can happen in one of two ways: if HDM2 SMIs
hinder the E3 ligase activity of HDM2, the protein product remains high and stabilized.
On the other hand, if HDM2 retains its HDM2 E3 ligase activity, degradation of itself is
possible, although it may also be possible that HDM2 still ubiquitinates p53 (or
additional proteins) even in the presence of HDM2 SMIs, reducing the stability of
reactivated p53.
To determine if HDM2 retains its autoubiquitination in the presence of HDM2
SMIs, a cell free autoubiquitination assay was performed using recombinant proteins.
Neither class of agents inhibits the E3 ligase function of HDM2 (Figure 4.1A).
Autoubiquitination of recombinant His-tagged HDM2 was not inhibited by the addition of
Nutlin-3, MI-319 or MI-219 at IC50 or even much higher (50 µM) concentrations after 1.5
hours incubation and subsequent separation onto a 4-20% SDS-PAGE gel. Disulfiram,
on the other hand, completely abrogated autoubiquitination at 10 µM, and was included
as a control.
The importance of this assay was not realized right away. It was not until some
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unusual observations were re-analyzed and interpreted that allowed for the
development of a retrospective hypothesis: that HDM2 inhibition by MI-219 alters the
functional activity of HDM2 and that it may correspond to biological activity. A key piece
of data that aided in such interpretation is shown in Figure 4.2. D24 treatment at 10 µM
showed autoubiquitination and degradation of recombinant HDM2 when immunoblot
with His-tagged antibody. The 60 kDa degratory fragment of HDM2 is clearly shown on
the blot. Since this was a cell free autoubiquitination assay, there were no indicators
that additional proteins could have enhanced HDM2 autoubiquitination and degradation.
Results supporting this hypothesis may help to explain the unexpected differences that
were noted in between each class of HDM2 SMI in Chapter 3.
Figure 4.1 HDM2 SMIs do not inhibit E3
ligase function of HDM2. Recombinant
His-tagged HDM2 was used in a cell free
autoubiquitination reaction. IC50 or 50 µM
of Nutlin-3, MI-219, or another spirooxindole compound, MI-319 was added to
the reaction for 1.5 hours. Lack of E2
enzyme, ubiquitin alone, disulfiram (DSF),
and DMSO vehicle were all included as
controls. Immunoblot using anti-ubiquitin
antibody was used to assess HDM2
autoubiquitination.
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Figure 4.2 A higher concentration of
zinc
ejector
D24
induces
autoubiquitination and degradation
HDM2. His-tagged HDM2 was
incubated in the presence or
absence
of
increasing
concentrations of zinc ejectors for
1.5 h in a cell free autoubiquitination
assay. Immunoblot was probed for
using anti-His tag antibody and
clearly detects the 60 kDa degratory
fragment of HDM2. Removal of zinc
from E3 ligases is supposed to
render them nonfunctional.

Based on this finding we hypothesized that these agents should induce HDM2
ubiquitination and degradation in cell based assays. We, therefore, re-examined the
effects of HDM2 SMIs on HDM2 protein expression in the WSU-FSCCL cells. Initial
experiments used 14% SDS-PAGE gels to separate whole cell lysates which are not
optimal for detecting posttranslationally modified proteins which prompted us to switch
to the 4-20% SDS-PAGE gels for further examination and confirmation of HDM2
modification upon HDM2 inhibition. Both full length and smaller size bands consistent
with degraded HDM2 were evident in MI-219-treated cells as early as 12 hours and
peaked at 24 hours (Figure 4.3A, B). Higher exposure also detected larger size band
consistent with autoubiquitinated HDM2 which occurred at the early time point (12
hours). HDM2 expression pattern in Nutlin-3-treated cells was similar to control with the
exception of a faint degraded band detected at 48 hours in the highest concentration
(10 µM). Similar effects were also observed in the wt-p53 KM-H2 and the L-591
Hodgkin lymphoma cell lines (Figure 4.3B, C). Interestingly, the higher molecular weight
species appeared to correspond to biological activity, as increased apoptotic cells were
apparent in the MI-219, but not the Nutlin-3, treated HL cells for 24 hours (Figure 4.3C).
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Figure 4.3 HDM2 autoubiquitination and degradation is detected in whole cell lysates
from treated wt-p53 WSU-FSCCL (A) and KM-H2 cells (B). Autoubiquitination appears
to occur at earlier time points, which then degrades full-length HDM2. C, HL cell line L591 also demonstrates higher molecular weight bands indicative of HDM2
autoubiquitination after a 24 hour exposure to HDM2 SMIs. This also appears to
correspond with increased apoptotic cells at the same time point.

To confirm the nature of the smaller molecular weight bands, we conducted an
immunoprecipitation (IP) experiment using WSU-FSCCL. After exposure to MI-219 or
Nutlin-3 for 12 hours, HDM2 protein was immunoprecipitated using 1:1 ratio of SMP-14:
D-12 antibodies (the former is known to detect degraded HDM2). Immunoblotting (IB)
with HDM2 polyclonal antibody (AF1244) revealed the full length HDM2 in addition to
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higher molecular weight species (likely autoubiquitinated HDM2) and ~60kDa band, the
major degraded species of HDM2 (Figure 4.4A). The intensity of this band was
concentration-dependent in MI-219-treated cells but was not seen in Nutlin-3-treated
cells. These findings suggest that MI-219 but not Nutlin-3 posttranslationally regulates
HDM2 protein by inducing autoubiquitination and degradation of itself as a way of
compensating for the high levels of HDM2 mRNA produced.

Figure 4.4 MI-219 enhances endogenous HDM2 self-ubiquitination and degradation. A,
WSU-FSCCL cells were treated with increasing concentration of HDM2 SMIs for 12h.
Cells were collected and subject to immunoprecipitation with a 1:1 ratio of mouse
monoclonal HDM2 antibodies (SMP-14: D-12) and blot using rabbit polyclonal HDM2
antibody AF1244. SMP-14 is known to detect the 60 kDa degraded fragment of HDM2.
B, WSU-FSCCL cells were treated with increasing concentration of HDM2 SMIs for 16h.
Prior to cell collection, cells were exposed to 10 µM of MG132 for 15 minutes to
preserve ubiquitinated proteins and were subject to immunoprecipitation as in B, but
blot with anti-ubiquitin monoclonal antibody.

Summary
The results from Chapter 4 strongly imply that MI-219, but not Nutlin-3, regulates
HDM2 destruction via autoubiquitination. Later time points (48 h) results in a reduction
of HDM2 protein, suggesting that enhancement of HDM2 E3 ligase activity occurs at
earlier time points to reduce the high levels of mRNA and protein produced from the
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p53-HDM2 autoregulatory loop. Therefore, p53 may be contributing to regulate its own
activity since this was not seen in mt-p53 lymphoma cells. Furthermore, it may also
correspond with biological activity since there appeared to be an association between
HDM2 destabilization and p53-dependent apoptotic response. The results show that
HDM2 retains its E3 ligase activity in the presence of Nutlin-3 and both MI compounds.
Various higher and lower molecular weight species were detected endogenously in
various lymphoma cell lines and primary lymphoma patient samples when treated with
increasing concentrations of MI-219, but not Nutlin-3.

This supports our proposed

mechanism of action for MI-219 that posttranslationally regulates or modifies HDM2 by
autoubiquitination and degrades itself as a way of compensating for the high levels of
HDM2 produced.
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CHAPTER V
CONCLUSIONS, SIGNIFICANCE AND FUTURE DIRECTIONS
Although the vast majority of lymphomas have high rates of remission induction
and survival with the current chemotherapy regimens, many patients still do not respond
well to therapy. Failure to respond to initial treatment or relapse following a brief
remission is typically the case. A majority of lymphomas retain wt-p53 status and have
developed mechanisms to compromise p53 signaling, such as HDM2 overexpression,
deletions in p14ARF, and viral oncogenes (141-143). It is clear that HDM2 plays an
important role in lymphoma tumorigenesis. HDM2 inhibitors R7112 (Nutlin-3 analog)
and JNJ-26854165 (a tryptamine derivative) are currently under clinical evaluation in
Phase I studies (NCT00623870, NCT00559533, NCT00676910) and the first results
have recently been published (129, 144). We previously investigated MI-319 in FL
(137), and have gained access to MI-219, the clinical grade spiro-oxindole and selective
activator of the p53 pathway in tumor cells, not in normal cells (139). Therefore, we
further examined the effects of targeting HDM2 in lymphoma cells in order to
understand the molecular mechanisms required to translate lab findings into clinically
relevant outcomes.
Limitations of primary lymphoma cells
Results produced from the cell lines were expected to be similar to those
obtained in the patient samples. Unfortunately this may not have entirely been the case
due to heterogeneity of the primary cell population. Although the protocol that was
performed for the majority of the lymphoma patient samples was optimized immensely
to enhance a purified B lymphocyte cell population, we cannot rule out potential
carryover of other cell types that may not have been excluded entirely in the process.
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However, we are confident that the biological responses observed post drug treatment
are predominantly due to B lymphocytes as flow cytometry confirmed the enhancement
of the CD19+ B lymphocyte population (Figure 3.7).
Whereas cell lines are relatively homogenous cell populations and have distinct
growth rates, primary derived B lymphocytes do not actively grow once they are
resuspended in media. Therefore, isolation, purification and drug treatment must be
performed right away otherwise cells will die off naturally, making it difficult to collect
enough cells for experimental analyses such as immunoblotting. A major limitation when
using patient derived B lymphocytes is the number of cells obtained. First, they do not
actively grow in RPMI media. The cells remain dormant or die off. Second, blood draws
vary in white blood cell count numbers from patient to patient and also depends on the
diagnosis and extent of disease. Third, cells are lost during the isolation and purification
process from multiple washes and from the monocyte and CD2+ T cell depletion steps.
Approximately 20-30 million B lymphocytes are lost from the initial extraction of PBMCs
to the resuspension of the final pellet of purified B cells. Yet another limiting factor is the
duplicity of experimental procedures. More often than not, there is only one opportunity
to process, set up, and analyze primary lymphoma patient samples. Therefore, it is of
utmost importance to use extra caution at each and every step up to and including data
analyses in order to make the most of the data obtained. There may be no chance to
redo an experiment if something goes awry due to that particular patient undergoing
chemotherapy, regression of disease with a possible reduction in that individual
patient’s cell counts the subsequent doctor visit, and progression may lead to a change
from the initial diagnosis (FL transforming into DLBCL).
The number of Annexin V positive cells in the untreated control was surprisingly
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high. Also, retrospectively looking back at this data, if one were to use flow cytometry to
monitor apoptosis for future patient samples, the TUNEL/PI kit may be the more suitable
choice, since both PI and FITC-labeled TdT enzyme must enter the nucleus after
fixation and do not rely on the integrity of the plasma membrane. Primary B
lymphocytes are much smaller and less robust than that of their cell line counterparts.
Consequently, this renders the plasma membrane much more susceptible to Annexin V
binding.

Additionally,

non-specific

Annexin

V

binding

causing

issues

(i.e.

megakaryocytes, platelets, some myeloid lineage cells) as well as Annexin V binding
buffers being proapoptotic (Ca2++) which sensitizes the delicate B lymphocytes and
may create false positives by exposing phosphatidylserine (145). PI can create false
positive by binding to cytosolic RNA, but these effects were minimized by treating each
sample with 1ug/ul of RNase prior to the addition of PI.
The molecular events upon HDM2 antagonism elicit stress responses through
nongenotoxic activation of p53. A number of lymphoma cell lines were used along with
a panel of primary B-cell lymphoma patient samples. The results indicate that HDM2
inhibition restored functional activity to wt-p53, but not mt-p53 lymphoma cells. We
performed a time-course analysis to achieve a better understanding of the
consequences of HDM2 inhibition on lymphoma cells. We showed that HDM2 SMIs
demonstrate growth inhibitory effects in a time- and dose-dependent manner with
increased sensitivity in wt-p53 lymphoma cells. Furthermore, molecular changes were
induced in the p53 pathway resulting in cell cycle arrest and apoptosis as the primary
consequences of growth inhibition.
The p53 regulated target genes p21, HDM2 and p53AIP1 were activated
following treatment in wt-p53 WSU-FSCCL cells, although the degree of activation
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varied depending on time point, dose, and HDM2 SMI selected for treatment. Mt-p53 RL
did not show significant activation of p53-target genes, confirming that HDM2 SMIs
primarily require wt-p53 in order to mediate its antitumor response (146). We noted that
the degree of induction of p53 and its transcriptional targets following treatment
corresponded to a concurrent upregulation in p53-target protein expression. One
perplexing finding was that of the significantly high levels of HDM2 mRNA associated
with upregulated HDM2 protein that was induced upon MI-219, but far less with Nutlin-3,
treatment (Figures 3.22 and 3.23). This was surprising to us since restoration of the
p53-HDM2 autoregulatory loop is known to decrease p53 protein levels and activity
(76). How then, does p53 remain activated in the presence of such high levels of
HDM2? HDM2 destabilization has previously been reported to correlate with p53
transcriptional activity and has been suggested to play an important role in determining
p53 response (96, 97). Additionally, we observed that HDM2 inhibitors do not inhibit the
ubiquitin E3 ligase activity of HDM2 (Figure 4.1). Interference with HDM2 selfdegradation could negate effects seen from p53 reactivation and potentially be
detrimental for the advancement of HDM2 SMIs into the clinic. Therefore, we postulate
that HDM2 may undergo rapid turnover due to forced autoubiquitination and
degradation in the presence of MI-219. Further studies are necessary to determine is
this is important in shaping p53 responses to HDM2 SMIs.
The results suggest that the molecular mechanism of p53 reactivation involves
disruption of the HDM2-p53 interaction which occurs posttranslationally. Treatment of
lymphoma cells with HDM2 SMIs caused p53 stabilization due to increased half-life and
decreased proteasomal degradation by HDM2. Therefore, accumulation of p53 protein
levels is due to release of p53 from HDM2 and not because of de novo protein
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synthesis or due to a reduction in proteasome activity. The results indicate that the
transcriptional activity could be attributed to HDM2-p53 disruption by HDM2 SMIs.
Here, we provide experimental evidence that MI-219 effectively reactivates functional
activity of wt-p53 in lymphoma cells by inducing apoptosis as the primary growth
inhibitory effect. The marked difference in biological response is more pronounced when
exposed to MI-219 than Nutlin-3. This was unexpected considering the low frequency of
p53 mutations and the amount of previous studies reporting on the relative sensitivity of
hematological malignancies to Nutlin-3 induced cell death. Instead, Nutlin-3 seemed to
elicit a strong cell cycle arrest as the primary growth inhibitory effect. This was not an
artifact of cell culture conditions as similar results were found in lymphoma cells isolated
from patient samples (Figure 3.16). However, considerable variability has been
demonstrated to affect cellular response upon Nutlin-3 treatment in wt-p53 cancer cells
as well. Certain cancer cell lines have been reported to possess Nutlin-sensitivity over
others (147-151). Whereas cancer cells typically undergo cell cycle arrest and
apoptosis, senescence, differentiation, and endoreduplication have also been described
(152). Furthermore, cell lines with MDM4 overexpression have been shown to confer
enhanced sensitivity to Nutlin-3 treatment (149, 153). Whether or not MDM4
overexpression is the cause of increased potency in our model system remains to be
determined.
It would be interesting to compare gene expression profiles to assess the
genome-wide involvement of Nutlin-3 and MI-219 treatment on lymphoma cells. By
comparing each individual treatment to control and each individual treatment to each
other, such data would provide insight as to what may be causing the different biological
responses. Additionally, proteomic analysis may also help to identify crucial cofactors
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that may be necessary for the induction of growth arrest compared to apoptosis.
Our data indicate that restoration of p53 activity is clearly diverse between each
class of HDM2 SMI in the context of human lymphoma cells. This difference was
particularly evident in the transcriptional activity of p53 target genes as well as the
degree of apoptosis seen in WSU-FSCCL cells. A recent study also noted a more
pronounced biological effect induced upon RITA treatment than after Nutlin-3A
treatment (154). They postulated that RITA enhanced p53 transcriptional activity for
numerous proapoptotic genes as the key difference in response. Although this could
also be true of MI-219, p53AIP1 was the only p53-dependent target gene tested in this
study. It would be interesting to monitor the consequences of p53 reactivation between
MI-219 and RITA in our cell lines, considering the distinct modes of p53 activation of
each. The dynamics of tight p53 regulation can be greatly attributed to the numerous
upstream and downstream molecules known to interact with and posttranscriptionally
modify p53 activity.
Additional functions of HDM2 exist besides downregulation of p53. For example,
HDM2 has been shown to interact with and regulate other proteins such as E2F1, p73,
Rb, etc. Although this study did not investigate these proteins, it is highly likely that one
explanation to the difference in drug susceptibility is due to modulation of HDM2
interacting proteins upon HDM2 inhibition. Previous studies observed disruption
between some of these proteins and HDM2 in the presence of Nutlin-3 in mt-p53 cells.
This may explain the p53-independent effects seen at higher concentrations in WSUDLCL2 and RL that were observed. Recent studies have suggested that specific p53interacting proteins can regulate the selectivity of p53 target gene activation (155). The
dynamics of tight p53 regulation can be greatly attributed to the numerous upstream
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and downstream molecules known to interact with and posttranscriptionally modify p53
activity.
It is plausible that each class of HDM2 SMI induced a conformational change in
HDM2 that may also explain the different biological effects seen. Accumulated
experimental evidence suggests that changes in the N-terminus can affect HDM2
folding. The Selivanova group (154) hypothesized that RITA binds to the N-terminal
region of p53 with fast kinetics, and then undergoes a slow conformational change that
prevents HDM2 binding. Krajewski et al (156) reported that RITA may not block the p53HDM2 interaction in vitro (using NMR) and that these changes propagate to the p53
core domain. More recently, HDM2 was found to bind to the C-terminal domain of p53
at its acid domain. This supports the co-immunoprecipitation results and indicates that
HDM2 can bind to p53 in the newly changed conformation upon treatment with MI-219.
However, these results remain puzzling considering that increasing concentrations of
MI-219 led to an increase in interaction. Further investigation is necessary to determine
whether scaffolding proteins or HDM2 isoforms are the cause of enhanced p53-HDM2
interaction. Since additional proteins interact with HDM2 at the region besides p53, it is
unclear how SMIs affect the interaction of these molecules and whether or not they may
play a role in antitumor response upon treatment.
Therefore, further investigation is necessary to understand the precise
mechanisms regulating modifications of reactivated p53 in the presence of HDM2 SMIs
and how to utilize such agents for combinational therapy. Moreover, future studies will
offer solutions to the therapeutic potential and shortcomings of HDM2 SMIs in not only
lymphoma, but in other cancer types as well. Altogether, these results provide
experimental evidence that p53 reactivation, particularly by MI-219, may prove to be
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therapeutically beneficial in lymphoma patients that retain wt-p53 status.
MI-219 is a selective activator of the p53 pathway. We compared four cell lines:
two wt-p53 and two mt-p53. Our results, which were consistent with those obtained for
other types of cancer, show that HDM2 inhibition restored functional activity to p53 in
WSU-FSCCL and KM-H2 lymphoma cells. We performed a time-course analysis to
achieve a better understanding of the consequences of HDM2 inhibition on lymphoma
cells. We show that HDM2 SMI demonstrate growth inhibitory effects in a time- and
dose-dependent manner with increased sensitivity in wt-p53 lymphoma cells.
The p53 regulated target genes p21, HDM2 and p53AIP1 were activated
following treatment, although the degree of activation varied from case to case. We
noted that the degree of induction of p53 and its transcriptional targets following
treatment correlated with the level of its protein product at designated time point.
Here, we provide conclusive experimental evidence that MI-219 effectively
reactivates functional activity of wt-p53 in lymphoma cells. The marked difference in
biological response is more pronounced upon MI-219 treatment than Nutlin-3 treatment.
This was unexpected considering the low frequency of p53 mutations and the amount of
previous studies reporting on the relative sensitivity of hematological malignancies to
Nutlin-3 induced cell death (157, 158). However, considerable variability has been
demonstrated to affect cellular response upon Nutlin-3 treatment in wt-p53 cancer cells
as well. Certain cancer cell lines have been reported to possess Nutlin-sensitivity over
others (159, 160).
Despite the promise of restoring wt-p53 activity by HDM2 SMIs, the successful
translation into the clinical has proven rather modest results. Clearly, researchers are
only scratching the surface in terms of the overall complexity of p53, HDM2 and their
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independent functions from each other. The question now becomes: how is it possible
to fully harness p53 reactivation to eliminate cancer cells?
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Lymphomas frequently retain wild-type (wt) p53 function but overexpress HDM2,
compromising p53 activity.

Therefore, lymphoma is a suitable model for studying

therapeutic value of disrupting HDM2-p53 association by small-molecule inhibitors
(SMIs). HDM2 SMIs have been developed and are currently under various stages of
preclinical and clinical investigation.

This study examined various molecular

mechanisms associated and biological effects of two different classes of HDM2 SMIs:
the spiro-oxindoles (MI-219) and cis-imidazoline (Nutlin-3) in lymphoma cell lines and
patient-derived B-lymphoma cells. Surprisingly, results revealed significant quantitative
and qualitative differences between these two agents. At the molecular level, effect of
Nutlin-3 was generally more delayed (48h) and was notable for inducing cell cycle
arrest.

These findings indicate a response to a low level cellular stress and are

supported by lower levels of p53 expression in Nutlin-3-treated cells. In contrast, MI-219
triggered an earlier response (12-24h), predominantly in the form of cell death
associated with higher levels of p53 expression. Neither agent interfered with the E3
ligase function of HDM2, as confirmed in a cell-free autoubiquitination assay.
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Interestingly, these results report for the first time a novel mechanism of HDM2
antagonism by MI-219 in wt-p53 lymphoma cells that stimulates HDM2 selfubiquitination. Additionally, it corresponds with biological response of anti-lymphoma
activity and may provide an explanation for the differences in efficacy between MI-219
and Nutlin-3. This study indicates that p53-HDM2 interaction and methods of its
disruption are more complex than is currently realized and suggests that stimulation of
HDM2 self-ubiquitinating activity may be a novel treatment strategy for lymphoma.

123
AUTOBIOGRAPHICAL STATEMENT
Angela M. Sosin
Education:
2012
Ph.D. in Cancer Biology-Wayne State University School of Medicine,
Detroit, MI (Minor: Pharmacology)
2005
B,S. in Microbiology and Molecular Genetics-Michigan State University,
East Lansing, MI (Area of concentration: Cell and Molecular Biology;
Medical Microbiology and Immunology)
Additional Training:
2011
Principals in Clinical Pharmacology-National Institute of Health, Bethesda,
MD (Course consisting of 31 lectures on the fundamentals of clinical
pharmacology as a translational scientific discipline emphasizing rational
drug development and exploitation in therapeutics.)
Awards:
2010 & 2011 Cancer Biology Travel Grant Award, Wayne State University School of
Medicine/Karmanos Cancer Institute
2007-2010 Interdisciplinary Biological Sciences Competitive Stipend, Wayne State
University School of Medicine
2008
Departmental Housing Award, Wayne State University School of Medicine
2005
Honorable Mention-Student Employee of the Year (nominated), MSU
2002
Dean’s List, Two-time recipient, College of Natural Science, Michigan
State University
Publications:
1. Sosin AM, Hwang C, Heath EI. Clinical translation of angiogenesis inhibitors in renal
cell carcinoma. In: Cancer Biology Review: A Case Based Approach. Stadler, W.
and Winters, R. (Eds.), Demos Medical Publishing, New York, NY (expected in
press: Winter 2013)
2. Shalhout S, Sosin A, Martin A, Holland T, Al-Katib A, Bhagwat AS. Germinal center
derived B-cell lymphomas contain extensive DNA damage. (in preparation)
3. Sosin AM, Zhou W, Bluth MH. PDGF isoforms are differentially expressed in
peripheral blood mononuclear cellular subsets. (in preparation)
4. Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib A. HDM2
antagonist MI-219 (spiro-oxindole), compared to Nutlin-3 (cis-imidazoline), regulates
p53 through enhanced HDM2 autoubiquitination and degradation in human
malignant B-cell lymphomas. Journal of Hematology and Oncology, 2012, 5: 57
5. Arnold AA, Aboukameel A, Sosin A, Smith P, Goustin AS, Mohammad RM, Al-Katib
A. I-Kappa-Kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in nonHodgkin's lymphoma. Molecular Cancer, 2010, 9: 228
6. Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S.,
Al-Katib AM. An MDM2 antagonist (MI-319) restores functions and increases the life
span of orally treated follicular lymphoma bearing animals. Molecular Cancer, 2009.
8: 115

